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ABSTRACT 
Montika Denise Bush: Secondary Prevention Methods after Acute Myocardial Infarction among 
Medicare Beneficiaries 
(Under the direction of M. Alan Brookhart) 
 
Objective: To describe the use of secondary prevention methods and to investigate the effect of 
cardiac rehabilitation (CR) initiation on hospitalization following myocardial infarction among 
older adults. 
Methods: Medicare beneficiaries having a myocardial infarction (MI) in 2008 and survived to 
discharge were eligible for this study. In aim 2, beneficiaries also had to survive 60 days post 
discharge and have a revascularization procedure during hospitalization. Competing risk analysis 
was used to estimate the cumulative incidence of adoption of secondary prevention 
recommendations such as initiating cardiac rehabilitation and the difference in the cumulative 
incidence of subsequent hospital admission between cardiac rehabilitation initiators and non-
initiators.   
Results: At 30 days post-MI 6.7% (95% CI: 6.5%, 6.8%) of beneficiaries included in aim 1 
initiated cardiac rehabilitation and 14.2% (95% CI: 14.0%, 14.5%) initiated by 1-year post-MI 
using competing risk analysis. From the Kaplan-Meier analysis, 6.9% (95% CI: 6.7%, 7.0%) and 
15.1% (95% CI: 14.8%, 15.3%) of beneficiaries initiated cardiac at 30 days and 1-year post 
myocardial infarction respectively. Overall 4.5% (95%CI: 4.4%, 4.6%) of patients died by 30 
days post myocardial infarction rising to 17.0% (95%CI: 16.8%, 17.3%) at 1 year post 
myocardial infarction. At 1-year post discharge, cardiac rehabilitation initiators in aim 2 had a 
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lower risk of recurrent MI (4.2% 95%CI: 3.5%, 5.1%), cardiovascular (15.7% 95%CI: 14.3%, 
17.2%), and all-cause (30.4% 95%CI: 28.8%, 32.1%) hospitalization than non-initiators (18.0% 
95%CI: 17.6%, 18.4%; 33.2% 95%CI: 32.5%, 33.8%). 
Conclusions: Cardiac rehabilitation participation was low in Medicare beneficiaries.  Outpatient 
cardiac rehabilitation was associated with a reduced risk of recurrent myocardial infarction, 
cardiovascular disease, and all-cause hospital admissions 1-year post discharge in older 
myocardial infarction survivors.  
.
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CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS 
1. Overview 
The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) 
recommends a multi-disciplinary approach for secondary prevention of cardiovascular events 
and death in patients with acute coronary syndromes that includes exercise training, risk factor 
modification, and psychosocial evaluation and counseling [1, 2].  These guidelines are 
implemented in practice with cardiac rehabilitation (CR) programs; however, the utilization of 
these programs is not well understood in the elderly [3].  Since CR clinical trials enrolled 
younger mostly white male participants, there exists an opportunity to understand the efficacy of 
these programs in older more gender diverse populations than has previously been studied. Since 
clinical trials and observational studies provided as support for these recommendations focused 
on the effects for each component individually, it is important to describe the use of these 
guidelines in combination in practice [1, 2].  While the clinical trials of cardiac rehabilitation 
focused on mortality benefits, few investigators reported the benefits of cardiac rehabilitation on 
specific cardiovascular or all-cause hospitalization after an MI [4, 5].  The goals of this study are 
to summarize the use of guideline recommendations after hospital discharge following 
myocardial infarction (MI) and to estimate the effects of outpatient cardiac rehabilitation on 
cardiovascular related hospitalizations and all-cause hospitalizations in an elderly US population. 
The knowledge provided by this study will inform patients, providers, and insurers about use and 
benefits of following guideline recommendations. 
 
 2 
 
2. Specific Aims 
Specific Aim 1: To describe the use of health care services related to guideline recommendations 
for secondary prevention of cardiac events after hospital discharge for MI among Medicare 
beneficiaries. 
Specific Aim 2: To estimate the effect of initiation of cardiac rehabilitation services after MI on 
subsequent hospital admission for MI, cardiovascular related events, or all-cause admissions.     
Hypothesis: Initiation of cardiac rehabilitation services within the first 60 days after MI 
hospital discharge will decrease the risk of subsequent hospitalization within 12 months.   
Specific Aim 3:  To estimate the effect of initiation of cardiac rehabilitation services after MI on 
subsequent hospital admission for MI, cardiovascular related events, or all-cause admissions in 
clinically relevant subgroups such as prescription fills for guideline recommended post-MI 
pharmacotherapy.     
Hypothesis: There is a difference in the effect of cardiac rehabilitation initiation on 
subsequent hospitalization after an MI between strata. 
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CHAPTER 2: BACKGROUND 
1. Heart Disease Burden 
Although the mortality rate associated with cardiovascular (CVD) events has decreased by 
30% over the 10-year period between 1998 and 2008, heart disease remains the leading cause of 
death in the United States with approximately 812,000 of the nearly 2.5 million deaths occurring 
in 2008 attributed to CVD events [6]. Rogers et al also reported that almost half of the CVD 
deaths (405,000) belonged in the coronary heart disease (CHD) category, a subset of the 
conditions used to define CVD that includes myocardial infarction. Based upon the National 
Health and Nutrition Examination Survey: 2005-2008, the prevalence of coronary heart disease 
in Americans at least 20 years old was 16.3 million people with approximately 85% being at 
least 60 years old [6]. Using unpublished data from the Cardiovascular Health Study and the 
Atherosclerosis Risk in Communities study, the American Heart Association estimates that 
610,000 new and 325,000 recurrent MI events occur annually [6, 7].  History of MI is a risk 
factor for subsequent heart disease and recurrent attack.  The percentage of people at least 65 
years at the time of their first MI who will have recurrent MI/fatal CHD, heart failure, or stroke 
within 5 years after MI is 22%, 20%, and 5% respectively for men and 22%, 23%, and 8% 
respectively for women [6].    
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2. Medicare Insurance Program 
Medicare is a governmental sponsored health insurance program for people over the age of 
65, those under age 65 with specific medical conditions.  Medicare coverage is comprised of four 
segments (www.cms.gov).  Part A is hospital based insurance and Part B is provider (i.e. doctors) 
based insurance.  Original Medicare only included Part A and B as government funded fee-for-
service coverage.  In 2008, enrollment in fee-for-service Medicare was high (76.4%) for 
beneficiaries 65 years of age and older (www.cms.gov).  The remaining beneficiaries were 
enrolled in Medicare Part C also known as Medicare Advantage which is insurance coverage 
provided by government approved private insurance companies.  Medicare Part D includes 
prescription drug coverage without respect to enrollment in either standard fee-for-service 
Medicare or Medicare Advantage plans.  The Centers for Medicare and Medicaid Services 
(CMS) is the government agency responsible for governance and administration of the Medicare 
program including approving private insurance companies and allowing the use of the 
administrative claims data for research. 
 
3. Overview of Secondary Prevention Guideline Recommendations 
Based upon trials conducted in the 1970’s and 1980’s, early recommendations for heart 
attack prevention included specific recommendations for antiplatelet/anticoagulation therapy, 
ACE inhibitor therapy, and Beta-blocker therapy [8].  Rehabilitation that includes physical and 
occupational therapy was recommended as early as 1993 [9].  As new drugs came to market, they 
were added to the guidelines.  The knowledge gained from multiple clinical trials and 
observational studies on secondary prevention of cardiovascular events has been synthesized into 
scientific statements and practice guidelines from the American Heart Association (AHA), the 
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American College of Cardiologist (ACC), the American Association of Cardiovascular and 
Pulmonary Rehabilitation (AACVPR), and the Agency for Health Care Policy and Research 
(currently the Agency for Health Research and Quality) [10, 11].  The core components of the 
secondary prevention guidelines include patient assessment, nutritional counseling, weight 
management, blood pressure management, lipid management, diabetes management, tobacco 
cessation, psychosocial management, physical activity counseling, and exercise training [10] 
(Appendix Table 1).  The focus of this study is on those health care services that can be identified 
using administrative claims data (cardiac rehabilitation services and evidence based 
medications).  
 
4. Cardiac Rehabilitation  
4.1. Introduction. 
In 1993, the World Health Organization (WHO) published a book that defined cardiac 
rehabilitation as “the sum of activities required to influence favorably the underlying cause of the 
disease, as well as the best possible physical, mental and social conditions, so that they may, by 
their own efforts, preserve or resume as normal a place as possible in the community. 
Rehabilitation cannot be regarded as an isolated form of therapy but must be integrated with the 
whole treatment of which it forms only one facet” [12].  In 1994, the American Heart Association 
(AHA) issued a scientific statement that similarly advocated exercise training, risk factor 
modification, and psychosocial counseling as the 3 main focus areas for cardiac rehabilitation in 
the United States [13].  Agency for Health Research and Quality (formerly Agency for Health 
Care Policy and Research) published first clinical practice guideline in October 1995 that 
recommended cardiac rehabilitation for secondary prevention. 
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4.2. Evidence of Efficacy. 
Cardiac rehabilitation is included as a Class 1 (useful/effective/beneficial) recommendation 
in the AHA/ACC guidelines for the management of patients with unstable angina and myocardial 
infarction [1, 14].  Several meta-analyses of randomized control trials which investigated the 
efficacy of cardiac rehabilitation program vs. usual care without exercise published showing the 
protective effect of cardiac rehabilitation programs after cardiac events on mortality with at least 
1 year of follow- up [4, 5, 15, 16].  The meta-analysis authors reported a reduction of 20% to 
26% in all-cause mortality, 26% to 36% in cardiac-related mortality, and 21% to 47% in 
recurrent infarction.  Meta-analysis results were statistically significant except for the 
intervention effect on recurrent infarction reported by Taylor et al.  A large observational study of 
the elderly using Medicare claims data reported reductions in 5 year all-cause mortality between 
21% and 34% using 3 different methods of analysis [17].  Although the results of the 
observational study are similar to the earlier clinical trials, the authors note there may still be 
residual confounding in their results.  The effects of different levels of cardiac rehabilitation 
therapy were reported by Suaya et al and Hammill et al [17, 18].  Although each study had a 
different definition for dose of therapy, they both reported that more therapy resulted in greater 
mortality reduction.  This result differs from the meta analyses by Heran et al and Taylor et al 
which did not find a significant difference in all-cause or cardiovascular mortality by dose of 
cardiac rehabilitation therapy.  The conflict in results could be related to the difference in 
definition of dose, the difference in study population, or the effect of residual confounding in the 
observational studies.   
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4.3. Medicare Coverage.  
Since 1982 Medicare has provided coverage for phase II (outpatient) cardiac rehabilitation 
services for beneficiaries who have had an acute MI in the last 12 months, had coronary artery 
bypass graft (CABG) surgery, or a stable angina diagnosis. Although Phase I (inpatient) CR is 
covered by Medicare while Phase III (maintenance) CR is not covered by Medicare neither are 
the focus of this study.  Initially Medicare coverage focused on medically supervised exercise 
training with ECG monitoring as necessary.  A policy update in 2005 (effective March 2006) 
added coverage for additional conditions such as heart valve repair and percutaneous 
transluminal coronary angioplasty and additional services such as risk factor modification 
education and counseling.  Medicare will cover 2 to 3 sessions per week for 12 to 18 weeks up to 
36 sessions without the need for special permission.  [19] 
4.4. Utilization. 
Despite the recognized benefit by the medical community as indicated by the class 1 
recommendation, cardiac rehabilitation is underutilized in the United States.  An observational 
study of Medicare beneficiaries who experienced an acute MI or had coronary bypass surgery in 
1997 reported that only 14% beneficiaries who had an MI as their index hospitalization initiated 
CR within the first year after their qualifying event [20].  The study investigators from a single 
center participating in the Get with the Guidelines program who identified acute MI patients 
hospitalized between 2002 and 2003 noted that only 19% of 718 patients referred to CR via the 
quality improvement plan protocols actually attended at least one session. [21].   
Research has shown that there are both system and individual level factors that contribute to 
this lack of participation in CR programs.  Much of the research on CR utilization has focused on 
how to increase referral for this service since intervention on the referral process is seen as the 
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rate limiting element in the utilization process.  Several review articles of factors that affect CR 
referral identified physician preference, patient visit to a cardiologist, and access to medical 
insurance as system factors that positively predicted CR referral [22, 23].  These reviews also 
identified demographic factors such as younger age, male gender, marriage, completing high 
school, and English speakers as positive predictors of CR referral.  The effect of race on CR 
referral was unclear based upon these reviews since the results in one study in each review 
showed race as a negative predictor while the another study in each review did not show an 
effect of race on CR referral.  The authors in both reviews noted that patients undergoing a 
CABG or percutaneous coronary intervention (PCI) procedure during hospitalization as well as 
those patients diagnosed with hypercholesterolemia or hypertension were more likely to be 
referred for CR.  In the analysis by Cortes et al current smoking was also identified as a predictor 
of CR referral but smoking status was not a predictor of CR referral by Jackson et al.  
Additionally Jackson et al identified physician endorsement, ease of access to transportation, 
proximity to facility, younger age, male gender, marriage, high education, insurance coverage, 
and a diagnosis of hypercholesterolemia or diabetes as positive predictors for CR use.  In an 
analysis of the Prospective Registry Evaluation outcomes after Myocardial Infarction: Events 
and Recovery (PREMIER), the authors identified male gender, marriage, high education, 
insurance coverage, hypercholesterolemia, and higher BMI as positive predictors of CR use 
within 1 month of acute MI and PCI, hypertension, and PAD as negative predictors during the 
same time period [24]. 
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In a recent study of outpatient CR participation in a single hospital-based center in Victoria, 
Australia, the predictors of attending CR included male gender, having a domestic partner, and 
close proximity (<30 km) to facility while predictors of not attending included each 1 year 
increment in age, non-surgical CVD discharge diagnosis, and moderate proximity (30km to 150 
km) to facility [25].  In this study, patients participating in at least 3 sessions of a 6-week 
program or 1 session of a 3-week program defined attendance.  Using a subset of hospitals 
participating in the AHA’s Get with the Guidelines Program (GWTG), Brown et al identified 
dyslipidemia, smoking, admitting diagnosis of STEMI, and use of CABG or PCI procedures 
during index hospitalization as predictors for referral for CR [26]. In a study of a single center 
participating in the GWTG program, the authors noted that while ethnicity was not a predictor of 
referral it was a predictor of enrollment [21] 
Qualitative research has identified similar barriers to CR participation. In a recent systematic 
review of semi-structured interviews and focus groups, Neubeck et al identified provider 
communication during hospitalization including recommendation or lack of recommendation, 
timing of CR discussion in relation to surgery, diagnosis or other health information, and 
inconsistency of advice as system barriers to enrolling in CR programs [27]. The authors also 
noted that transportation issues, conflicts with work schedule, and language differences as other 
system barriers to CR participation.  On an individual level, the authors reported that patient 
participation in CR was affected by a patient's understanding and feelings toward the focus of 
CR sessions (exercise or psychosocial), a patient's understanding of their ability to modify CVD 
risk factors, and a patient's perceived embarrassment or perceived support and enjoyment from 
participation. 
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4.5. Potential Confounders. 
The following directed acyclic graph (DAG) was created based upon a review of the 
literature described previously in this document.  According to this diagram, the minimally 
sufficient adjustment set for estimating the effect of cardiac rehabilitation on outcomes includes 
age, comorbidity, previous medication, and current medication. 
 
  
Figure 2.1: Directed Acyclic Graph Describing the Association of Cardiac Rehabilitation to Outcomes 
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5. Evidence Based Medications  
5.1. Introduction. 
Secondary prevention guidelines recommend prescribing antiplatelet, beta blockers, ACE 
inhibitors, and statins at acute MI event discharge to reduce the risk of subsequent events.  Each 
medication has a Class I (useful/effective/beneficial) recommendation for coronary heart disease 
patients and specific sub-populations as defined in Table 2.1 [11].  Updates to guidelines 
recommend the use of statins in all post-MI patients removing the LDL-C restrictions on the 
class I recommendation of statins post-MI [28]. 
Table 2.1: Secondary Prevention Guideline Medication Recommendations 
Medication Class LOE Sub-Population by Condition 
Aspirin I A All 
Clopidogrel I B 
Acute coronary syndrome or percutaneous coronary 
intervention (PCI) with stent placement 
Β-Blocker I A All 
ACE inhibitors I A 
Left ventricular ejection fraction (LVEF) ≤40%, 
hypertension, diabetes, or chronic kidney disease 
ACE inhibitors I B All other patients 
Angiotensin 
receptor blockers 
I A 
Intolerant of ACE inhibitors and have heart failure 
or have had a MI with LVEF ≤ 40% 
Angiotensin 
receptor blockers 
I B All other patients intolerant of ACE inhibitors 
Statin I A LDL-C is ≥100 mg/dL 
Statin IIa B LDL-C is 70 to 100 mg/dL, 
LOE=Level of evidence: A – From multiple clinical trials, B – From 1 clinical trial 
or any number of observational studies 
Class I – Recommended to perform; Class IIa – Reasonable to perform 
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1. Antiplatelet therapy. 
Clinical trials have shown that antiplatelet medications are effective at reducing the risk of 
adverse cardiovascular events by inhibiting the formation of harmful blood clots.  In meta-
analyses of clinical trials conducted between 1976 and 1986, the Antiplatelet Trialists' 
Collaboration reported a 25% decrease in the odds of CVD event (MI, stroke, CVD death) and a 
30% decrease in the odds of non-fatal MI in those who used antiplatelet therapy compared to 
those who did not [29].  The Antithrombotic Trialists' Collaboration completed an updated meta-
analysis with similar results [30].  In meta-analyses of randomized trials conducted between 
2001 and 2006 investigating dual therapy with clopidogrel and aspirin compared to aspirin 
monotherapy showed a reduction in the risk of the combined outcome of MI, stroke, and death of 
12% to 26% [31, 32].  The authors' also note that while antiplatelet therapy is effective in 
reducing harmful cardiovascular outcomes there is also an increased risk in major bleeding 
events.    
 
2. Beta adrenergic receptor antagonism (Beta Blocker therapy). 
Similar to antiplatelet therapy clinical trial evidence for the effectiveness Beta Blocker (BB) 
therapy has existed since the 1970’s.  Research on the biologic pathways where BB therapy has 
been shown protective against future events is by the drug's effect on heart rate, arterial pressure, 
and muscle function [33, 34].  An early systematic review of clinical trials, reported a 20% 
reduction in the odds ratio of death and 24% reduction in the odds ratio of re-infarction in 
patients randomized to BB therapy compared to control [35].  While use of BB therapy as a class 
has been shown in clinical trial to reduce post-MI mortality, systematic review and meta-analysis 
of clinical trials provide inconclusive evidence between different subclasses [36].  Williams et al 
and DiNicolantonio et al reported that nonselective BB therapy had a greater benefit in reducing 
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mortality than selective BB therapy while Freemantle et al and Andersen et al did not report any 
difference in morality between subclasses [34, 37-39].  
3. Renin-Angiotensin System Inhibition (ACEi/ARB therapy).  
Research has shown that ACE inhibitors are effective in reducing cardiac events in those with 
and without heart failure.  The authors in a meta-analysis of placebo-controlled clinical trials of 
the use of ACE inhibitors after acute MI initiated between 1990 and 1997 reported a 17% 
reduction in odds of all-cause mortality and 18% reduction in the odds of cardiovascular 
mortality in those randomized to ACE inhibitors compared to those randomized to placebo [40].  
The trials included in the Domanski meta-analysis mainly included patient with heart failure or 
left ventricle systolic dysfunction.  Three  randomized placebo-controlled trials that included 
patients without heart failure but with atherosclerosis, reported a 14% reduction in odds of all-
cause mortality and 18 % reduction in the odds of non-fatal myocardial infarction [41].  
Approximately 60% of the patients in this second meta-analysis had an MI prior to study entry.  
In the analysis of five placebo-controlled trials of ACE inhibitors in patients with heart failure or 
left ventricle systolic dysfunction, Dagenais et al. also reported a 20% reduction in the odds of 
non-fatal myocardial infarction.  ACE inhibitors, a vasodilator, work on the angiotensin II 
pathway to affect blood flow and prevent tissue remodeling. ACE inhibitors are used in the 
treatment of hypertension and also reduce insulin resistance [42]. Aldosterone receptor blockers 
(ARB) also work on the angiotensin II pathway and have fewer issues with adherence than ACE 
inhibitors; however, there is not the same level of evidence of ARBs effectiveness in preventing 
further MI events as with ACE inhibitors [42] .  Guidelines recommend use of ARBs in 
secondary prevention only when ACE inhibitors are not tolerated by patients.    
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4. Cholesterol lowering via HMG-CoA reductase inhibition (Statin therapy).  
Statin therapy reduces the risk of CVD events by limiting the amount of cholesterol in the 
bloodstream.  The authors in a meta-analysis of placebo-controlled trials of elderly patients (≥ 
65years old at randomization) with coronary heart disease reported a 22% reduction in the 5 year 
relative risk for all-cause mortality and a 26% reduction in the 5 year relative risk for non-fatal 
MI events [43].  In a recently published meta-analysis of randomized trials evaluating statin 
therapy the results from the placebo-controlled secondary prevention trials showed an 18% 
reduction in the odds of all-cause mortality and a 31% reduction in the odds of major coronary 
events [44]. 
 
5.2. Evidence of Efficacy of Combination Pharmacotherapy. 
Several studies have been conducted investigating the use of guideline recommended 
medications after acute coronary syndrome (ACS) or acute MI.  Two studies from the University 
of Michigan investigated the effect of combination therapy defined by appropriateness score on 
1-year (Mukherjee et al.) and 2-year (Lahoud et al.) mortality in patients recently discharged for 
acute MI or unstable angina.  The appropriateness score categorized the number of medications 
used at discharge divided by the number of medications recommended by in the AHA/ACA 
guidelines where a participant did not have a documented contraindication [45, 46].  Level 1 
appropriateness specified that a patient used 1 medication where 3 or 4 were recommended while 
level 4 denoted all recommended medications were used.  Besides the differences in the length of 
follow-up, the Mukherjee study investigated the use of antiplatelet therapy while the Lahoud 
study specified the investigation of aspirin. Both studies included the use of ACE inhibitors or 
ARBs, statins, and β Blockers in calculation appropriateness.  Regardless of these differences, 
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both studies reported significantly decreased odds of mortality starting at an appropriateness 
level of 2 compared to reference Level 0 [46] or reference Level 0 or 1 [45].   Lahoud et al also 
reported decreased odds of hospitalization for non-fatal CVD events at 2 years at appropriateness 
level 2 or better in men compared to reference Level 0 or 1.  Combination therapy in women did 
not show an effect on non-fatal CVD events.  Nichols et al. compared users of 3 or 4 guideline 
medications to users of less than 3 medications (referent group) using electronic medical records 
from Kaiser Permanente, Northwest [47].  These authors' reported a reduction in all-cause 
mortality, HR (95%CI): 0.84 (0.73 – 0.98), in those who received all guideline medications 
compared to the reference group.  The hazard ratios for any CVD hospitalization and the 
composite outcome of CVD hospitalization and all-cause mortality were close to 1 and not 
statistically significant. 
Internationally Wong et al investigated the effect of aspirin, beta blockade, statin, and 
ACEi/ARB on survival among ACS patients admitted to two centers in New Zealand while 
Danchin et al investigated the use of similar medications on a population of acute MI patients 
admitted to intensive care units in France [48, 49].  All 1025 participants in the Wong study were 
using aspirin at hospital discharge.  The authors’ reported a protective 1 year mortality rate 
(HR=0.55 [95% CI: 0.30, 1.00]) for those using aspirin, statin, and beta blocker compared to 
aspirin and beta blocker without regard to use of ACEi/ARB in either group adjusting for 
continuous GRACE (global registry of acute coronary events) score only.  Danchin et al reported 
a protective 1 year mortality rate (HR=0.43 [95% CI: 0.28, 0.66]) for those initiating triple 
combination therapy (antiplatelet, beta blocker, and statin) compared to those who did not initiate 
triple therapy adjusting for the propensity for being prescribed triple combination therapy.  
Danchin et al reported that hyperlipidemia, admission Killip class 1, PCI during index 
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hospitalization were positive predictors of triple combination therapy while age, atrial 
fibrillation, and history of peripheral vascular disease, chronic renal failure, or congestive heart 
failure were negative predictors of triple combination therapy in their study.    
 
5.3. Medicare Coverage.  
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 made 
prescription drug coverage available beginning January 1, 2006 for Medicare beneficiaries who 
elected to enrolled in the program [50]. Premiums are income based such that low income 
beneficiaries who are also Medicaid eligible will have very limited out-of-pocket expenses and 
beneficiaries who have an income over a set poverty criteria will be required to an annual or 
monthly premium, deductible, and a variable percentage of the actual drug cost [50]. The 
copayment percentage starts at 25% drops to 0%, coverage gap, then increases to 5% based upon 
predefined spending limits [50]. While over the counter aspirin is not covered by the Medicare 
benefit, either generic or brand name options of each of the other medications are covered by 
Medicare. 
 
5.4. Utilization. 
Medication therapy cannot be effective if prescriptions are not filled.  In a study of primary 
non-adherence, not filling first prescription, for cardio-protective medication after acute MI, 
Jackevicius et al reported that approximately 18% of approximately 12,000 discharge 
prescriptions for cardiac medication from 4600 eligible patients were not filled within 90 and 
120 days after index hospitalization [51]. Restricting results to the four evidence based 
medication categories, antiplatelet agents (including aspirin) had the most unfilled prescriptions 
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(44%) while the other three medication had an average of 6% of unfilled scripts within 120 days 
of index discharge.  In a study of Medicare beneficiaries who had an acute MI in 2007, 
investigators reported that within 1 month of index hospitalization 59%, 51%, 54%, and 46% of 
beneficiaries filled a prescription for ACEi/ARB, beta blocker, statin, and clopidogrel 
respectively [52].  Zuckerman et al noted in their sample that prevalence of use declined by less 
than 7% of beneficiaries for ACEi/ARB, beta blocker, and statin medications over the 33 month 
follow-up period while a greater decline was observed in clopidogrel prevalence.  In a study of 
patients with coronary artery disease who had a catheterization procedure, the authors reported 
that of those who were prescribed the medication at discharge 78%, 67%, 47%47%, and 40% of 
patients self-reported use of aspirin, beta blocker, ACEi, and statin at one year respectively [53]. 
Reasons for non-adherence to cardiovascular therapy are similar to those of non-initiation of 
cardiac rehabilitation.  Jackevicius et al reported that age, income level, number of prescribed 
medications prior to index MI, medication counseling during index hospitalization, having a PCI 
procedure, history of heart failure, and history of MI were related to primary non-adherence to 
all verse none of the therapies in a patient's post MI evidence based treatment regimen [51].  
Investigators from the MAINTAIN study reported that age, less educational attainment, lack of 
pharmacy benefits, number of discharge medications, lack of medication reminder strategies, 
being a dialysis patient, and having peripheral vascular disease were all negatively associated 
with persistence with the evidence based treatment regimen prescribed at discharge [54, 55].  
Melloni et al also reported that previous revascularization was positively associated with 
persistence with the evidence based treatment regimen prescribed at discharge.  
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6. Utilization of Multiple Guideline Recommendations. 
Most of studies of secondary prevention focus on exercise therapy or pharmacotherapy 
separately, did not include antiplatelet medications in their analysis, or did not comment on use 
of cardiac rehabilitation [56].  However, Chew et al investigated six month outcomes in patients 
in the global registry of acute coronary events (GRACE) cohort who were exposed to services 
and treatment with several in-hospital guideline recommendations including discharge 
prescriptions and referral to cardiac rehabilitation services [57].  The authors conducted a nested 
case-control study reporting the proportion of deaths that could be prevented by better-quality 
utilization of guideline recommendations.  Of the medications and services of interest, the 
attributable fraction associated with increased survival was highest for thienopyridine antiplatelet 
usage (clopidogrel) (10.9% [95% CI: 2.3, 9.8]) and lowest for beta blockade (0.1% [95% CI: -
2.8, 4.8]). The attributable fraction for cardiac rehabilitation referral was also in the top three but 
had a very wide confidence interval (10.6% [95% CI: -2.4, 21.5]).  
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CHAPTER 3: METHODS 
1. Data 
The original research data application to the Chronic Condition Warehouse (CCW) requested 
claims data for Medicare beneficiaries who were hospitalized in 2008 with a discharge diagnosis 
in the primary or secondary position of acute myocardial infarction (AMI) defined by 
International Classification of Diseases, Clinical Modification 9th revision (ICD 9) discharge 
codes of 410.xx (excluding 410.x2) and were continuously enrolled in Medicare parts A, B, and 
D from January 1, 2007 to death or December 31, 2009.  Starting from this original set of 
beneficiaries, the initial population defined for this dissertation excluded those who had an MI 
hospitalization in the year prior to their index event in 2008, had history of substantial frailty 
(diagnosis of paralysis, Parkinson’s disease, or bed sores; or evidence of use of a wheelchair or 
in-home hospital bed) in the year prior to their index event [58], were less than 65 years old at 
the time of their index event, or did not survive their index hospitalization.    Methods used to 
further define the study population for each aim are described in subsequent sections of this 
document.  A cohort study using Medicare data is a cost effective method for investigating this 
study question since elderly patients do not traditionally meet the eligibility requirements for 
clinical trials. 
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2. Assessment of Guideline Recommend Therapy 
Guideline recommended therapy components had a common definition for all aims. 
Healthcare Common Procedure Coding System (HCPCS) codes from outpatient and carrier CMS 
files for Physician services for outpatient cardiac rehabilitation with (93798) or without (93797) 
continuous ECG monitoring were used to identify cardiac rehabilitation (CR) for this 
dissertation.  Prescription claims from CMS Part D files were linked using National Drug Codes 
(NDCs) and/or generic names of medications to Anatomical Therapeutic Chemical (ATC) codes 
to identify medications of interest for this dissertation.  Guideline recommend medications 
(GRM) were identified by ATC codes B01AC for Platelet Aggregation Inhibitors excluding 
heparin, C10 for HMG CoA Reductase Inhibitors (Statins) and other Lipid Modifying Agents, 
C09 for Renin-Angiotensin System Inhibitors (ACEi and ARB), C07 for Beta Blockers. 
Exposure to any Lipid Modifying agent were summarized separately from Statin exposure.  
Although platelet inhibitors such as aspirin have multiple indications we assumed that utilization 
at prescription strength in this populations is for secondary prevention of cardiovascular events.  
Combination GRM use was defined by days' supply remaining for all four GRMs for 
beneficiaries where revascularization occurred during index period or all GRMs except 
antiplatelet therapy otherwise. 
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3. Competing Risk Analysis 
In the analysis of survival data, any event that prevents the outcome of interest from 
occurring is a competing event. Death from any cause is a competing event in analyses of non-
fatal outcomes. In aim 1 of this project, the outcomes of interest were the initiation of cardiac 
rehabilitation and concurrent adoption of multiple guideline recommendations while the 
outcomes of interest in aim 2 and 3 were disease specific hospitalization and all cause 
hospitalization after an index MI.  An absolute measure of each outcome was computed using 
cumulative incidence functions (CIF).  The CIF, F(t), was computed using a nonparametric 
competing risks method defining death as the only competing event.  
𝑭(𝒕) = 𝑷𝒓(𝑻 ≤ 𝒕, 𝑴 = 𝒎) = ∑ (
𝒅𝒎𝒊
𝒏𝒊
) ∏ (𝟏 −
𝒅𝒋
𝒏𝒋
 )𝒊−𝟏𝒋=𝟏
 
𝒕𝒊≤𝒕
 (1) 
 where events from cause m=1 is the event of interest and m=2 was death from any cause, ti 
is a distinct list of event times, dmi is the number of events of interest from cause m that occur at 
time ti, ni is the number of individuals in the risk set just before time ti, dj is the number of events 
of any cause that occur at time tj, and nj is the number of individuals in the risk set just before 
time tj.   
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4. Methods Specific to Aim 1 
The 12 months before the index hospitalization period was used to define baseline covariates.  
The index hospital period began with the MI admission and ended when the patient was 
discharged into the community (loss of inpatient status) based upon the discharge destination 
codes (Appendix Table 2). If a beneficiary remained an inpatient by being transferred to another 
medical facility then the index period ended when the beneficiary was discharged into the 
community after the final continuous transfer. Guideline concordant medical care was assessed 
from the end of the index hospitalization period until December 31, 2009. 
Cohort restriction by post-MI survival time (30, 60, 90, 180, and 366 days) and predicted 1-
year mortality <17% (Gagne score <5) defined six subpopulations for analysis in Aim 1.  The 
Gagne comorbidity score has been shown to predict mortality better in elderly populations than 
other comorbidity measures [59].  Initiation of CR, guideline adoption of combination 
medication, and guideline adoption of CR and combination medication were outcomes of interest 
for Aim 1. We estimated the unadjusted cumulative incidence function (CIF) of guideline 
concordant care within the first year post-MI overall and by survival restricted populations. 
Study outcomes were used to describe the differences in the CIF computed from competing risk 
estimators and Kaplan-Meier estimators in the overall population and predicted 1-year mortality 
population.  The CIF computed from the complement of the Kaplan-Meier product limit 
estimator of the survival distribution function estimates the probability of study outcomes before 
some time t censoring beneficiaries who die before the experiencing the outcome of interest. In 
this aim, we also described the differences in the CIF between the overall population and each 
subpopulation.  Descriptive statistics (count, proportions, mean, standard deviation) were used to 
summarize the baseline characteristics of each population. 
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5. Methods Specific to Aim 2 
The 12 months before the index hospitalization period was used to define baseline covariates.  
The index hospital period began with the MI admission date and ended when the patient was 
discharged into the community (loss of inpatient status) based upon the discharge destination 
codes (Appendix Table 2). If a beneficiary remained an inpatient by being transferred to another 
medical facility then the index period ended when the beneficiary was discharged into the 
community after the final continuous transfer. The use of outpatient cardiac rehabilitation was 
assessed in the 60-day exposure window following the index hospitalization period.  Outcomes 
were assessed from the end of the 60-day exposure period until December 31, 2009. 
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CHAPTER 4: USING TIME-TO-EVENT AND COMPETING RISKS APPROACHES TO 
ASSESS PATTERNS OF USE OF HEALTHCARE SERVICES AFTER AN INDEX 
EVENT 
 
1. Introduction. 
Healthcare utilization databases are increasingly used to assess quality of care and identify 
characteristics of patients and providers that may be indicative of sub-optimal treatment and 
guideline compliance [24, 27, 60].  In the literature, these studies assess how patients are 
managed after an index event, such as myocardial infarction (MI) [4, 5, 35, 40, 42, 44]  or 
fracture [61, 62].  The results of such studies can be used to shape policy, identify disparities, and 
design quality improvement activities.   Large healthcare utilization databases can be used to 
identify these index events and then assess whether patients are receiving recommended 
prescription medications or follow-up healthcare services. 
An important methodological consideration in conducting studies of treatment initiation or 
guideline compliance is how to account for death and loss to follow-up in the study design and 
analysis.  Investigators can restrict the study cohort by requiring patients to survive and not be 
lost to follow-up for a specific time window.  However, selecting patients who survive the 
window limits generalizability of results when the source population is subject to high mortality 
and/or the window interval is too long.  Dropping patients from the study who die or are 
censored during follow-up can also lead to selection bias as conditioning on survival or being 
uncensored can create spurious associations between baseline covariates and the outcome (e.g., 
guideline compliance).  In the analysis, investigators can use Kaplan-Meier estimators to censor 
 25 
patients who die or treat death as a competing event by using competing risk methods.  In a 
standard Kaplan-Meier time-to-event analysis, patients are followed from a study defined start 
time until an event of interest occurs or until they are censored.  Assuming non-informative 
censoring, this approach results in an estimate of the percentage of patients who had an event of 
interest at a point in time as if the risk of censoring could be removed.  When patients are 
censored because of death, this target estimation is sub-optimal since the risk of death cannot be 
removed. Alternatively, competing risk models can be used to estimate the percentage of patients 
who would initiate treatment before death.   
In the present paper, we use time to adoption of guideline recommendations for secondary 
prevention in heart disease patients from the American Heart Association (AHA) as an empirical 
example to investigate the implication of implementing these different methods to account for 
death in post-MI Medicare beneficiaries [63].    We first examined how increasing survival 
requirements affected the characteristics of the study cohort. We then compared the Kaplan-
Meier estimates of the percentage of patients receiving recommended treatments to estimates 
from competing risk approaches.  The goal of this study was to illustrate how employing 
competing risk analysis is preferable to survival restriction and censoring at death in the analysis 
of health care utilization after an anchoring event.  This study also illustrates how guideline 
recommendations are being utilized in a large elderly population.  While use of these guideline 
components have been described separately less is known about concurrent use of 
recommendations.  
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2. Methods. 
2.1. Data/Study Population 
We used data from the Centers for Medicare and Medicaid Services (CMS) to investigate 
prescription fills of guideline recommended medications (GRMs) and use of outpatient cardiac 
rehabilitation services after myocardial infarction (MI).  Medicare beneficiaries who were 
hospitalized in 2008 for MI defined by discharge code 410.xx (excluding .x2) in first or second 
position, were 65 to 95 years old at the time of their index and were continuously enrolled in 
Medicare Part A, B, and D between January 2007 and death or end of 2009 were included in our 
study.  Beneficiaries were included in this study if they survived their index hospitalizations and 
had a community based discharge destination code (Appendix Table 2).  Beneficiaries were 
excluded from this study if they had an MI hospitalization in the year prior to their index event in 
2008 or had evidence of substantial frailty (diagnosis of paralysis, Parkinson’s disease, or bed 
sores; or evidence of use of a wheelchair or in-home hospital bed) in the year prior to their index 
event [58].      
 
2.2. Study Design 
The 12 months before the index hospitalization period was used to define baseline covariates 
(Figure 4.1).  The index hospital period began with the admission date of the first MI 
hospitalization in 2008 and ended when the patient was discharged into the community (loss of 
inpatient status) based upon the discharge destination codes (Appendix Table 2). If a beneficiary 
remained an inpatient by being transferred to another medical facility then the index period 
ended when the beneficiary was discharged into the community after the final continuous 
transfer. Guideline concordant medical care was assessed from the end of the index 
hospitalization period until December 31, 2009. 
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2.3. Variable Definitions 
Demographic characteristics (e.g., age, gender, and racial status) were obtained from the CMS 
enrollment file.  Comorbidities and procedures were identified using the Medicare Standard 
Analytic Files using International Classification of Diseases Ninth (ICD 9) Revision codes, 
Current Procedural Terminology (CPT) codes, and Healthcare Common Procedure Coding 
System (HCPC) codes.   We identified relevant baseline and index period characteristics such as 
history of hypertension, hyperlipidemia, revascularization, and length of stay. The Gagne 
comorbidity score, which predicts mortality better in elderly populations than other comorbidity 
measures, was computed from the baseline characteristics [59].  Frailty was quantified by 
computing the probability of diminished activities of daily living using model coefficients [58]. 
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2.4. Outcome Definitions 
Therapies of interest in our study were initiation of outpatient CR defined by records with 
CPT codes 93797 and 93798 and concordant use of GRMs identified in Part D records. 
Guidelines recommend prescriptions for antiplatelet medication, renin-angiotensin system 
inhibitors, beta adrenergic receptor antagonism, and HMG CoA reductase inhibitors (statins) for 
MI survivors.  Aspirin is also recommended however, it is not reliably captured in Part D records 
because of it’s over the counter availability.  Concordant use of GRMs was defined as the first 
day after index period that a beneficiaries had any days' supply remaining for a combination of 
all four GRMs for beneficiaries where revascularization occurred during index period or all 
GRMs except antiplatelet therapy otherwise. We also identified guideline concurrent care (GCC) 
as the first date when beneficiaries were using both GRMs and CR services. In the definition of 
concurrent use of CR and GRMs, a beneficiary was assumed a user of CR indefinitely after CR 
initiation while prescription fill dates and days’ supply of medication defined combination GRM 
discontinuation. If a beneficiary discontinued combination GRM use before CR initiation then 
they would not be considered a concurrent user until they started using the appropriate level of 
combination GRMs again.    
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2.5. Cohort Restrictions  
We explored the effect of requiring survival for varying lengths of time on the post-MI use of 
GRMs and/or CR services.  We considered five different post-MI discharge survival restrictions: 
30, 60, 90, 180, and 366 days.  The 30, 60, and 90-day time intervals were based the common 
lengths of days' supply for GRMs. The 180-day and 1-year time points were chosen to represent 
extreme scenarios [64].  We also created a cohort restricted by Gagne comorbidity score [59]. 
Gagne et al defined high risk of 1-year mortality as ≥ 17%.  We defined the final restricted 
population as beneficiaries with a comorbidity score <5 to define a population with a lower risk 
of 1-year mortality.     
 
2.6. Statistical Analysis 
Descriptive statistics (count, proportions, mean, standard deviation) were used to summarize 
the characteristics of each population. Standardized differences between the overall population 
and each restricted population were computed.  Kaplan-Meier estimates were used to compute 
the risk of death post-MI.  Two methods were used to estimate the cumulative incidence function 
(CIF) of guideline concordant care.  First, CIF estimates were computed from the complement of 
the Kaplan-Meier (KM) product limit estimator of the survival distribution function, 1-S(t) in 
which individuals were censored by both death and end-of-study.  Let T be the time from 
discharge to the event of interest (i.e. CR initiation) or censoring. Under those conditions, the 
complement of the Kaplan-Meier estimator estimates the probability of CR initiation before 
some time t, CIF(t) = Pr(T<t), assuming all censoring events are independent of CR initiation.  
The larger the proportion of the population that dies before CR initiation, the higher the degree to 
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which the independence assumption is violated since death prevents the event of interest from 
occurring.    
For the competing risk approach, let T be the time from discharge to censoring, death, or use 
of guideline recommended health care whichever comes first and let J be an indicator variable 
that specifies the type of event.  Let J have a value of 1 when T refers to prevention method (i.e. 
CR initiation), 2 when referring to death before prevention method, and 0 when referring to 
censoring occurring before an event of either type. The competing risk method estimates the joint 
probability of a specific event occurring before a given time point, CIF(t) = Pr(T<t , J=j) which 
can be interpreted as the probability of CR initiation before death at time t when J=1. In the 
competing risk approach, the population at risk at each event time excludes individuals who have 
had any event before time t [65].  This method allows investigators to estimate the CIF for the 
event of interest (initiation of CR) and any competing event (death) separately. The estimator 
assumes that each cause specific event type is independent of each other [66]. SAS uses a 
nonparametric estimator to calculate cumulative incidence, CIF(t) = (number of deaths at time t 
from cause j/ number at risk at t) *(KM estimate of survival at time t-1) [67].   To describe the 
difference between these approaches, note that for the KM approach CIFKM(t) = 1 – SKM(t) and 
for the competing risk approach CIFj=1(t) + CIFj=2(t) = 1 – SJ(t).  All analyses were done using 
SAS 9.4 or greater. 
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3. Results. 
We identified 78,479 beneficiaries who met study criteria and who averaged 405 days of 
follow-up time.  The overall population had an average age 78 years old and 56% of 
beneficiaries were female (Table 4.1).  The most common comorbid conditions in the study 
population were hypertension (84%), hyperlipidemia (66%), congestive heart failure (46%), and 
diabetes, (41%). As we restricted the study cohort by increasing amounts of post-MI survival 
time, the number of beneficiaries in each population decreased, however, there were very few 
differences in the distribution of measured baseline characteristics (Table 4.1).   Differences in 
the measured covariates occurred in the 366-day restricted population which had greater than 
10% standardized differences from the overall population for revascularization during index 
period, probability of diminished daily activities (frailty proxy), and Gagne score that were (data 
not shown).  The proportion of beneficiaries with an index period revascularization procedure 
increased while the mean frailty probability and comorbidity score decreased with increasing 
restriction on survival time for population inclusion.  In addition, the proportion of beneficiaries 
at least 85 years old at the time of their index MI decreased with increasing restriction on 
survival time so each restricted population is slightly younger than the overall population.  The 
survival rate in the overall population was lower than in the survivor-restricted populations 
(Figure 4.2). The proportion of those who died in the overall population was 4.5% at 30 days 
post-MI increasing to 17% at 1-year post-MI. The proportion of those who died at 1 year was 
13.1%, 11.0%, and 9.3% in 30-day survivor, 60-day survivor, and 90-day survivor populations 
respectively.  The survival-restricted population survival curves were similar in shape to the 
overall population survival curve with a shift to the right for each additional increment in 
required survival time for inclusion in the population.  
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Estimates of guideline adoption increased with increasing amounts of survival restriction 
(Table 4.2).  Differences in the cumulative incidence between each subsequent survivor-
restricted population were small. When the survival requirement for population inclusion was 90 
days or less, the confidence intervals for the cumulative incidence of treatment for each survivor 
restricted population overlapped. However, confidence intervals for the cumulative incidence of 
treatment did not overlap when at least 180 days of survival were required for population 
inclusion. The difference in cumulative incidence estimates between the unrestricted population 
and each survivor-restricted population was larger at 1-year post-discharge than at 30 days post-
discharge. Cumulative incidence of treatment adoption for the predicted lower mortality 
population was similar to the 1-year survivor restricted population for each study treatment. 
We observed that the Kaplan-Meier (KM) estimates of the incidence of CR initiation 
overestimated the competing risk method estimates.  The magnitude of the difference in 
estimates between methods increased with an increase in time since discharge (Table 4.2).  At 30 
days post-MI, the difference in CR initiation between KM estimate and the competing risk 
estimate was only 0.2.  However, at 1-year post-MI, the difference between estimation methods 
was 0.9. Although the estimates for CR initiation were higher in the comorbidity score restricted 
population than the unrestricted population, the difference between estimates was similar, 0.2 
and 0.7 at 30 days and 1-year post-MI respectively.  The incidence of CR initiation was low 
regardless of the estimation method used ranging from 6.7% at day 30 to 17% at 1 year post-
discharge depending on the estimation method and population analyzed (Table 4.2).   
Similar to the cumulative incidence for initiating CR, the KM estimates for post-MI GRM 
use and guideline concurrent care were higher than the competing risk estimates (Table 4.2).  
Approximately, 30% of the each population already had prescription fills for the concordant 
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number of GRMs at MI discharge.  At 30 days post discharge, the competing risk method 
estimated 42.6% (95%CI: 42.2%, 42.9%) of the overall population with concordant GRM use 
while the KM method estimated 42.8% (95%CI: 42.5%, 43.1%) with concordant GRM use. At 
1-year post discharge, the proportion of beneficiaries with concordant GRM use rose to 51.4% 
(95%CI: 51.0%, 51.7%) using competing risk estimator and 52.9% (95%CI: 52.5%, 53.2%) 
using the KM estimator.  Less than 10% of any of the populations were concurrently compliant 
with both CR and combination GRMs within 1 year of MI discharge. 
Cumulative incidence curves produced using the competing risk estimator for each study 
treatment and the respective competing event of death are presented in Figure 4.3.  CR initiation 
and guideline concurrent care curves start to peak at approximately 90 days post discharge then 
remain relatively constant after 180 days.  The cumulative incidence for post-MI GRM use, 
however, increases rapidly before 90 days post discharge and continues to increase after 90 days 
but at a slower rate than before 90 days.  The magnitude of the cumulative incidence of death 
before CR initiation was similar to the magnitude of the cumulative incidence of CR initiation.  
The magnitude of death before GRM use was lower than the magnitude of death before CR 
initiation.  At 1-year post discharge, 17% and 11% died before initiation CR and concordant use 
of GRMs respectively.   
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4. Discussion. 
In a population-based study of patients discharged alive after MI, we compared different 
approaches to estimating the percentage of patients receiving guideline-recommended 
medications or initiating cardiac rehabilitation after hospital discharge. Restricting the study 
cohort by survival reduced the population at risk and appeared to select for more guideline 
obedient patients, as restriction increased the estimated number of patients who would initiate 
CR and GRM during follow-up. Censoring patients who die is an alternative approach to 
requiring survival; however, implicitly censoring by death assumes that patients who die could 
still go on to initiate therapy. The solution to the problems presented in the paper is to use 
competing risk analysis with or without further restriction by comorbidity score.  In our study, 
we saw relatively modest differences between the Kaplan-Meier estimates of the cumulative 
probability of initiation of CR and GRM and the competing risk estimates.  In studies subject to 
stronger mortality, these differences would be larger.  
Our estimates of CR initiation were similar to other studies where the differences in results 
are likely a result of differences in the populations studied or analysis methods. A previous study 
of Medicare beneficiaries at least 65 years old who survived at least 30 days post discharge and 
had a length of stay of 30 days or less reported 13.9% of MI patients initiated CR within 1 year 
[20].  A more recent study of patients at least 65 years old at MI hospitalization admitted to 
hospitals volunteering to participate in a national MI registry reported that 20.4% of MI patients 
(32.6% of referred patients) initiated CR within 1-year post-MI [68]. Doll et al, required survival 
1-week post discharge but also restricted their population by prescriptions for GRMs [68].  Both 
of these studies reported the observed proportion of CR initiators from their initial cohorts 
without accounting for the competing event of death, therefore, these estimates would be higher 
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than estimates in similar populations from the current study.  Promoting the use of CR programs 
remains an opportunity for public health intervention given that less than half of any population 
studied participated in at least 1 session with in the first year post-MI discharge.   
 Beneficiaries were more likely to fill prescriptions for concordant guideline medications 
than participate in cardiac rehabilitation in this study.  Concordant GRM use from this study was 
more similar to a study of acute coronary syndrome (ACS) patients with commercial health plans 
(37.5% at 6 months) than to registry study of commercially insured patients with cardiovascular 
disease (56% at 6 months) [64, 69].  Although more beneficiaries filled prescriptions for GRMs 
than initiated CR, the change in the proportion of participation from 30 days to 1-year post-MI 
was the similar for both CR and concordant GRMs in populations where 6 months or less of 
survival was required for inclusion.  Approximately one-half of those who initiated CR within 
the first year post-MI were also concurrently using 3-4 GRMs.  
Results from our analysis have implications for outcome studies using guideline treatments 
as an exposure. Beneficiaries experienced long delays between discharge and CR initiation. The 
proportion of CR initiators nearly doubled between 30 days and 90 days post discharge.  The 
mean time to CR initiation of 56 days in this study was similar to what has previously been 
reported [17]. However, the distribution of time to initiation among initiators was skewed right 
(median 33 days); so, if we restricted our population using the mean time to initiation as the 
criterion for inclusion then more than half of those who would eventually initiate treatment 
would be included in the restricted population.  Assuming 75% of eventual CR initiators do so 
within a 60 day exposure widow and it takes 180 days for 95% of eventual CR initiators to start, 
methods presented by Austin et al suggest an outcome hazard ratio of 0.73 when the true 
outcome hazard ratio was 0.75 using Monte Carlo simulations [70]. Survival bias in this case is 
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overestimating the protective effect of treatment but not by very much. Studies that aim to assess 
the effects of CR should consider the above factors when designing outcome studies with fixed 
exposure windows.   
Restriction has been used in the study of the effect of protective treatments on mortality and 
morbidity outcomes to reduce biases associated with conducting these studies using 
observational data [71-73]. Cohorts restricted by baseline characteristics such as comorbidity 
score may introduce some selection bias but they may reduce confounding by indication.  We 
demonstrated that treatment adoption by comorbidity-restricted population was similar to the 1-
year survival restricted population. We would recommend that investigators restrict cohorts by 
baseline prediction of survival than actual survival in the extreme case of 1-year survival for 
cohort eligibility. 
 Our large sample size was a strength of our study.  It permitted us to apply several types of 
restrictions and maintain sufficient numbers of beneficiaries in each subpopulation to stably 
estimate adoption of guideline recommendations.  Women, a subgroup that is often under-
represented in CR trials, comprised approximately half of each population [4].  Because we used 
both outpatient and pharmacy claims data for this study, we were able to avoid recall bias in the 
definition of treatment assignments.  However, we may have underestimated GRM use due to 
over-the-counter aspirin use and some beneficiaries initiating treatment on samples or low-cost 
generic medications that were not recorded in the pharmacy claims [74, 75].  Unlike GRM use, 
CR services should be reliably captured in the outpatient claims data since providers would not 
be reimbursed without submitting a claim.  Unlike GRM use, CR services should be reliably 
captured in the outpatient claims data since providers would not be reimbursed without 
submitting a claim.  
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In conclusion, we discussed different approaches to accounting for death applied to a study of 
the use of guideline-recommended therapies after MI.   We found that restricting the population, 
as is commonly done, resulted in somewhat higher estimates of CR and GRM use.  We saw 
relatively modest differences between the Kaplan-Meier estimates and the competing risk 
estimates.  In studies where mortality is more common, restricting the study to patients who 
survive may affect generalizability and may introduce some survivor bias in the results.  In these 
settings, competing risk approaches would be preferable. 
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5. Tables 
Table 4.1: Characteristics of Study Populations 
Characteristics Overall 
030 Day 
Survivors 
060 Day 
Survivors 
090 Day 
Survivors 
180 Day 
Survivors 
366 Day 
Survivors 
Comorbidity 
Score 
Overall 78,479 74,948 (95.5%) 73,187 (93.3%) 71,815 (91.5%) 68,737 (87.6%) 63,770 (81.3%) 64,317 (82.0%) 
Demographics        
   Age        
      Mean (SD) 77.9 ( 7.57) 77.7 ( 7.51) 77.6 ( 7.48) 77.6 ( 7.46) 77.5 ( 7.42) 77.3 ( 7.36) 77.7 ( 7.56) 
   Gender        
      Female 43,947 (56.0%) 41,930 (55.9%) 40,914 (55.9%) 40,135 (55.9%) 38,403 (55.9%) 35,523 (55.7%) 35,901 (55.8%) 
   Minority        
      Yes 10,641 (13.6%) 10,175 (13.6%) 9,916 (13.5%) 9,725 (13.5%) 9,297 (13.5%) 8,574 (13.4%) 8,062 (12.5%) 
Index 
Hospitalizations 
       
   Revascularization        
      Angioplasty 28,639 (36.5%) 28,185 (37.6%) 27,924 (38.2%) 27,703 (38.6%) 27,113 (39.4%) 26,050 (40.8%) 25,890 (40.3%) 
      CABG 6,970 ( 8.9%) 6,892 ( 9.2%) 6,853 ( 9.4%) 6,819 ( 9.5%) 6,727 ( 9.8%) 6,444 (10.1%) 6,237 ( 9.7%) 
   Any ICU Stay 43,304 (55.2%) 41,417 (55.3%) 40,488 (55.3%) 39,742 (55.3%) 38,095 (55.4%) 35,365 (55.5%) 35,365 (55.0%) 
   Any CCU Stay 29,774 (37.9%) 28,658 (38.2%) 28,115 (38.4%) 27,659 (38.5%) 26,629 (38.7%) 24,934 (39.1%) 24,898 (38.7%) 
   Discharge Home        
No Hospital 
Transfers 
59,300 (75.6%) 56,603 (75.5%) 55,338 (75.6%) 54,356 (75.7%) 52,152 (75.9%) 49,134 (77.0%) 49,270 (76.6%) 
Baseline 
Medications 
       
Baseline 
Doughnut Hole 
Gap 
26,455 (33.7%) 25,052 (33.4%) 24,349 (33.3%) 23,784 (33.1%) 22,536 (32.8%) 20,453 (32.1%) 19,323 (30.0%) 
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Characteristics Overall 
030 Day 
Survivors 
060 Day 
Survivors 
090 Day 
Survivors 
180 Day 
Survivors 
366 Day 
Survivors 
Comorbidity 
Score 
Baseline 
Comorbidities 
       
Proxy Frailty 
Mean (SD) 
6.4 ( 6.47) 6.2 ( 6.21) 6.1 ( 6.08) 6.1 ( 5.99) 6.0 ( 5.84) 5.8 ( 5.58) 5.7 ( 5.23) 
Comorbidity 
Score Mean (SD) 
2.4 ( 2.49) 2.3 ( 2.44) 2.3 ( 2.42) 2.2 ( 2.39) 2.1 ( 2.35) 2.0 ( 2.30) 1.5 ( 1.58) 
Conditions        
     Hypertension 65,653 (83.7%) 62,829 (83.8%) 61,401 (83.9%) 60,296 (84.0%) 57,765 (84.0%) 53,572 (84.0%) 53,935 (83.9%) 
     Hyperlipidemia 51,936 (66.2%) 50,136 (66.9%) 49,188 (67.2%) 48,407 (67.4%) 46,645 (67.9%) 43,709 (68.5%) 43,114 (67.0%) 
Congestive 
Heart Failure 
36,153 (46.1%) 33,796 (45.1%) 32,602 (44.5%) 31,647 (44.1%) 29,505 (42.9%) 26,332 (41.3%) 23,875 (37.1%) 
Uncomplicated 
Diabetes 
32,260 (41.1%) 30,798 (41.1%) 30,071 (41.1%) 29,438 (41.0%) 28,012 (40.8%) 25,723 (40.3%) 24,389 (37.9%) 
Cardiac 
Arrhythmia 
29,533 (37.6%) 27,884 (37.2%) 27,061 (37.0%) 26,397 (36.8%) 24,984 (36.3%) 22,762 (35.7%) 21,035 (32.7%) 
Chronic 
Pulmonary 
Disease 
26,868 (34.2%) 25,375 (33.9%) 24,557 (33.6%) 23,945 (33.3%) 22,546 (32.8%) 20,376 (32.0%) 18,437 (28.7%) 
Electrolyte 
Disorders 
22,731 (29.0%) 21,157 (28.2%) 20,377 (27.8%) 19,783 (27.5%) 18,547 (27.0%) 16,709 (26.2%) 13,791 (21.4%) 
Deficiency 
Anemia 
22,213 (28.3%) 20,879 (27.9%) 20,162 (27.5%) 19,562 (27.2%) 18,330 (26.7%) 16,449 (25.8%) 13,171 (20.5%) 
Osteoporosis or 
Osteoarthritis 
21,576 (27.5%) 20,665 (27.6%) 20,194 (27.6%) 19,802 (27.6%) 18,995 (27.6%) 17,639 (27.7%) 17,360 (27.0%) 
Peripheral 
Vascular 
Disease 
18,058 (23.0%) 17,090 (22.8%) 16,585 (22.7%) 16,141 (22.5%) 15,235 (22.2%) 13,823 (21.7%) 11,759 (18.3%) 
     Cancer 9,919 (12.6%) 9,157 (12.2%) 8,774 (12.0%) 8,492 (11.8%) 7,856 (11.4%) 7,050 (11.1%) 5,901 ( 9.2%) 
Cerebrovascular 
Disease 
9,505 (12.1%) 8,932 (11.9%) 8,666 (11.8%) 8,431 (11.7%) 7,960 (11.6%) 7,186 (11.3%) 6,516 (10.1%) 
Renal Disease 4,890 ( 6.2%) 4,496 ( 6.0%) 4,320 ( 5.9%) 4,136 ( 5.8%) 3,763 ( 5.5%) 3,268 ( 5.1%) 1,038 ( 1.6%) 
Rheumatic 
Disease 
3,837 ( 4.9%) 3,685 ( 4.9%) 3,617 ( 4.9%) 3,543 ( 4.9%) 3,399 ( 4.9%) 3,134 ( 4.9%) 3,097 ( 4.8%) 
Note: Cells highlighted in yellow have a standardized difference between the restricted population and the overall population that is greater than 
10%. 
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Table 4.2: Post-MI Cumulative Incidence Estimates of Cardiac Rehabilitation Initiation, Concordant GRM, and Guideline Concurrent 
Care by Restriction and Calculation Method at Selected Time Points 
Analysis Restriction Days Since Discharge 
Type Method 30 60 90 180 366 
Cardiac Rehabilitation 
Competing Risk None 6.7 ( 6.5, 6.8) 10.9 ( 10.6, 11.1) 12.4 ( 12.2, 12.6) 13.7 ( 13.4, 13.9) 14.2 ( 14.0, 14.5) 
Kaplan-Meier 
None 6.9 ( 6.7, 7.0) 11.3 ( 11.1, 11.5) 13.0 ( 12.8, 13.3) 14.4 ( 14.2, 14.7) 15.1 ( 14.8, 15.3) 
030 Day Survivors 7.0 ( 6.8, 7.2) 11.4 ( 11.2, 11.6) 13.1 ( 12.9, 13.3) 14.5 ( 14.3, 14.8) 15.2 ( 14.9, 15.4) 
060 Day Survivors 7.1 ( 6.9, 7.3) 11.6 ( 11.4, 11.8) 13.3 ( 13.1, 13.5) 14.7 ( 14.4, 15.0) 15.3 ( 15.1, 15.6) 
090 Day Survivors 7.2 ( 7.0, 7.4) 11.8 ( 11.6, 12.0) 13.5 ( 13.3, 13.8) 14.9 ( 14.6, 15.2) 15.6 ( 15.3, 15.8) 
180 Day Survivors 7.5 ( 7.3, 7.7) 12.2 ( 12.0, 12.5) 14.0 ( 13.7, 14.2) 15.4 ( 15.2, 15.7) 16.1 ( 15.8, 16.3) 
366 Day Survivors 7.9 ( 7.7, 8.1) 12.8 ( 12.6, 13.1) 14.7 ( 14.4, 15.0) 16.2 ( 15.9, 16.5) 16.8 ( 16.5, 17.1) 
Predicted 1-yr 
Survivors 7.9 ( 7.7, 8.1) 12.9 ( 12.7, 13.2) 14.8 ( 14.5, 15.1) 16.3 ( 16.0, 16.6) 17.0 ( 16.7, 17.3) 
Competing Risk 
Predicted 1-yr 
Survivors 7.7 ( 7.5, 7.9) 12.5 ( 12.3, 12.8) 14.3 ( 14.0, 14.6) 15.7 ( 15.4, 16.0) 16.3 ( 16.0, 16.6) 
Guideline Recommend Medication (GRM) 
Competing Risk None 42.6 ( 42.2, 42.9) 45.1 ( 44.8, 45.5) 46.5 ( 46.2, 46.9) 48.9 ( 48.6, 49.3) 51.4 ( 51.0, 51.7) 
Kaplan-Meier 
None 42.8 ( 42.5, 43.1) 45.6 ( 45.2, 45.9) 47.1 ( 46.8, 47.5) 49.8 ( 49.5, 50.2) 52.9 ( 52.5, 53.2) 
030 Day Survivors 43.5 ( 43.1, 43.8) 46.2 ( 45.9, 46.6) 47.8 ( 47.4, 48.1) 50.5 ( 50.1, 50.8) 53.4 ( 53.1, 53.8) 
060 Day Survivors 43.8 ( 43.4, 44.1) 46.5 ( 46.2, 46.9) 48.1 ( 47.7, 48.4) 50.7 ( 50.4, 51.1) 53.7 ( 53.3, 54.0) 
090 Day Survivors 44.0 ( 43.6, 44.3) 46.7 ( 46.4, 47.1) 48.3 ( 47.9, 48.6) 50.9 ( 50.6, 51.3) 53.9 ( 53.5, 54.2) 
180 Day Survivors 44.4 ( 44.0, 44.7) 47.1 ( 46.8, 47.5) 48.7 ( 48.3, 49.1) 51.3 ( 51.0, 51.7) 54.2 ( 53.9, 54.6) 
366 Day Survivors 44.9 ( 44.5, 45.3) 47.7 ( 47.3, 48.1) 49.2 ( 48.8, 49.6) 51.9 ( 51.5, 52.3) 54.8 ( 54.4, 55.2) 
Predicted 1-yr 
Survivors 44.7 ( 44.3, 45.1) 47.5 ( 47.1, 47.9) 49.1 ( 48.7, 49.5) 51.7 ( 51.3, 52.1) 54.6 ( 54.2, 55.0) 
Competing Risk 
Predicted 1-yr 
Survivors 44.5 ( 44.1, 44.9) 47.2 ( 46.8, 47.6) 48.6 ( 48.2, 49.0) 51.0 ( 50.6, 51.4) 53.5 ( 53.2, 53.9) 
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Analysis Restriction Days Since Discharge 
Type Method 30 60 90 180 366 
Guideline Concurrent Care 
Competing Risk None 3.3 ( 3.2, 3.4) 5.1 ( 5.0, 5.3) 5.9 ( 5.8, 6.1) 6.9 ( 6.7, 7.0) 7.6 ( 7.4, 7.8) 
Kaplan-Meier 
None 3.4 ( 3.3, 3.5) 5.3 ( 5.2, 5.5) 6.2 ( 6.0, 6.4) 7.3 ( 7.1, 7.4) 8.1 ( 7.9, 8.3) 
030 Day Survivors 3.4 ( 3.3, 3.6) 5.4 ( 5.2, 5.6) 6.2 ( 6.1, 6.4) 7.3 ( 7.1, 7.5) 8.1 ( 7.9, 8.3) 
060 Day Survivors 3.5 ( 3.4, 3.6) 5.5 ( 5.3, 5.7) 6.3 ( 6.2, 6.5) 7.4 ( 7.2, 7.6) 8.2 ( 8.0, 8.4) 
090 Day Survivors 3.6 ( 3.4, 3.7) 5.6 ( 5.4, 5.8) 6.4 ( 6.3, 6.6) 7.5 ( 7.3, 7.7) 8.3 ( 8.1, 8.5) 
180 Day Survivors 3.7 ( 3.6, 3.8) 5.8 ( 5.6, 6.0) 6.7 ( 6.5, 6.9) 7.7 ( 7.5, 7.9) 8.6 ( 8.4, 8.8) 
366 Day Survivors 3.9 ( 3.7, 4.0) 6.1 ( 5.9, 6.3) 7.0 ( 6.8, 7.2) 8.1 ( 7.9, 8.4) 9.0 ( 8.8, 9.2) 
Predicted 1-yr 
Survivors 4.0 ( 3.8, 4.1) 6.2 ( 6.0, 6.4) 7.1 ( 6.9, 7.3) 8.3 ( 8.1, 8.5) 9.2 ( 9.0, 9.4) 
Competing Risk 
Predicted 1-yr 
Survivors 3.9 ( 3.7, 4.0) 6.0 ( 5.8, 6.2) 6.9 ( 6.7, 7.1) 8.0 ( 7.8, 8.2) 8.8 ( 8.6, 9.0) 
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6. Figures 
Figure 4.1: Study Design 
 
 
Figure 4.2: Study Population 1 Year Survival Curve 
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Figure 4.3: Competing Risks Estimates of Cumulative Incidence of Cardiac Rehabilitation (CR) 
Initiation, Concordant Guideline Recommended Medication (GRM) Use, and Guideline 
Concurrent Care (GCC) After MI  
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CHAPTER 5: EFFECT OF INITIATING CARDIAC REHABILITATION AFTER 
MYOCARDIAL INFARCTION ON SUBSEQUENT HOSPITALIZATIONS IN OLDER 
ADULTS 
 
1. Introduction. 
History of myocardial infarction is prevalent in 7.6 million people over the age of 20 in the 
US based upon a recent national survey with approximately 85% occurring in adults ≥ 60 years 
old [76].  Patients with a history of MI have a higher risk of a recurrent MI or other 
cardiovascular disease (e.g. heart failure, stroke) than the overall population [76].  Recurrent MI 
or cardiovascular related death was estimated to occur in 17% of men and 21% of women ≥ 45 
years old within five years of their initial MI [76].  The American College of Cardiology 
Foundation/American Heart Association (ACCF/AHA) guidelines for secondary prevention of 
cardiovascular events and management of patients with acute coronary syndromes recommend 
use of evidence-based medications and participation in outpatient cardiac rehabilitation programs 
for MI survivors to reduce the high risk of these future events [63].  
Cardiac rehabilitation (CR) programs showed a protective effect on mortality similar to 
pharmacotherapy when compared to usual care in meta-analyses of randomized control trials 
comprising patients hospitalized with a myocardial infarction or acute coronary syndrome [4, 5]. 
While the clinical trials in these meta-analyses focused on mortality benefits, few investigators 
reported the benefits of CR on specific cardiovascular or all-cause hospitalization after an MI.  
Meta-analysis of studies of the association of CR and subsequent hospitalization after an index 
event were heterogeneous so the evidence for the benefits of CR on these outcomes is not as 
strong as the evidence for mortality benefit [16, 77].  Since CR clinical trials enrolled younger 
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mostly white male participants, there exists an opportunity to understand the efficacy of these 
programs in older more gender diverse populations than has previously been studied. 
Additionally, because many of the clinical trials investigating CR were completed several 
decades ago, there is some debate if CR programs still provide a benefit in the modern medical 
environment [77, 78].   Given the large proportion of the population that is effected by recurrent 
cardiovascular events and the strength of evidence on the efficacy of CR programs in older 
adults with a history of MI, it is essential to investigate the routine and optimal use of secondary 
prevention methods in this population.   
The goal of this study was to investigate the effect of initiating outpatient cardiac 
rehabilitation within 60 days post-MI on cardiac related and all-cause hospitalizations in a 
modern medical environment.  For each type of hospital admission outcome, the 1-year risk 
difference between the CR initiators and non-initiators was computed among Medicare 
beneficiaries.  Since CR services are underutilized in practice, we also performed stratified 
analyses by age, comorbidity score, and secondary prevention medication use to explore 
subpopulations that can be targeted future intervention efforts to improve participation in CR 
programs [20, 79].  
 
2. Methods 
2.1. Study Population 
All Medicare beneficiaries between 65 and 88 years old who were hospitalized between 
January 1, 2008 and December 31,2008 for acute MI, had a revascularization procedure during 
the index hospitalization period, and were continuously enrolled in Medicare Part A, B, and D 
between January 2007 and death or December 2009 were eligible for this study.  We defined 
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acute MI hospitalization by International Classification of Diseases, Clinical Modification 9th 
revision (ICD 9) diagnostic code 410.xx (excluding 410.x2) in the first or second discharge 
position of hospital summary data from Medicare Provider Analysis and Review (MedPAR) 
files. Revascularization was identified from ICD 9 procedure codes, Healthcare Common 
Procedure Coding System (HCPCS) codes, and Current Procedural Terminology (CPT) codes 
(Appendix Table 4).  Beneficiaries were excluded from this study if they had an MI 
hospitalization in the year prior to the index MI, had evidence of substantial frailty (i.e. 
diagnoses for paralysis, Parkinson’s disease, bed sores) in the year prior to the index event [58], 
did not survive the index hospitalization, or died within 60 days of index discharge. Beneficiaries 
were also excluded from this study if they did not have a community designated index discharge 
destination code (Appendix Table 2) or had a length of hospital stay greater than 153 days.   
The 12 months before the index hospitalization period was used to define baseline covariates 
(Figure 5.1).  The index hospital period began with the MI admission date and concluded at 
discharge after any contiguous transfers to other facilities if applicable.  If a beneficiary 
remained an inpatient by being transferred to another medical facility then the index period 
ended when the beneficiary was discharged into the community after the final continuous 
transfer.  The use of outpatient cardiac rehabilitation was assessed in the 60-day exposure 
window following the index hospitalization period.  Outcomes were assessed from the end of the 
60-day exposure period until December 31, 2009. The institution review board (IRB) at the 
University of North Carolina at Chapel Hill approved this study. Individual informed consent 
was waived by the IRB in this secondary data analysis study. 
  
 47 
 
2.2. Measures 
Outcomes 
The primary outcome for this study was hospital admission for an acute MI identified by 
ICD9 code 410.xx during the follow-up period.  Secondary outcomes were hospitalization for 
any reason or a major adverse cardiovascular and cerebrovascular event (MACE) defined as a 
hospital record for acute MI, angina, heart failure, or stroke identified by the following ICD 9 
discharge diagnosis codes: 410.xx, 411.1, 428.xx, 430, 431, 432, 433.x1, 434.x1, 435, 436 [59].  
We used bone fractures at any location as a negative control outcome (Appendix Table 3). 
Beneficiaries were administratively censored on December 31, 2009 (end of follow-up).  
Mortality was defined by the presence of a date of death in Medicare enrollment data. 
Cardiac rehabilitation 
CR initiation was defined by an occurrence of HCPCS codes 93797 and 93798 in Medicare 
data within the 60-day exposure period.  
Covariates 
We identified demographic and clinical characteristics as potential confounders.  Information 
on age and gender was obtained from Medicare enrollment file. The 2010 American Community 
Survey was used to assess median household income categories (<= $30,000, $30,001-$60,000, 
$60,001-$100,000, $100,001-$150,000, >=$150,001) at census block group level.   Health care 
utilization during baseline and index hospitalization period was used to define comorbid 
conditions [59, 80]. The Gagne score, used to measure comorbidity status in the primary 
analysis, was categorized to eliminate small cell sizes by grouping all values less than zero into a 
single category, scores of 5 and 6 into a single category, and all values greater than 7 into a 
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single category [59].  Using the model coefficients reported by Faurot et al, we estimated the 
probability of diminished daily activities as a proxy for frailty [58].  Additional baseline 
cardiovascular and frailty related comorbid conditions were investigated as potential confounders 
(Appendix Table 5).  Hospitalization characteristics such as hospital, intensive care unit, and 
coronary care unit lengths of stay were also considered as potential confounders.  Intensive care 
and coronary care unit stays were dichotomized (any or none) for analysis. 
Guideline recommended medication (GRM) utilization during baseline and exposure periods 
as well as baseline use of other cardiovascular medication were also included in analyses as 
potential confounders [14, 81].   Guidelines recommend the use of antiplatelet therapy, beta-
blockade therapy, angiotensin converting enzyme inhibitors (ACE), angiotensin receptor 
blockers (ARB), and Statins [14].  Prescription claims from Medicare Part D files linked using 
National Drug Codes (NDCs) and/or generic names of medications to Anatomical Therapeutic 
Chemical (ATC) codes were used to identify medications of interest for this study.  Although 
platelet inhibitors such as aspirin have multiple indications, we assumed that utilization at 
prescription strength in this population was for prevention of cardiovascular events.   
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2.3. Statistical Analysis  
Descriptive statistics were used to describe characteristics of the study population. 
Standardized differences were calculated to detect differences between CR initiators and non-
initiators.  The number of person years of follow-up, number of events, and the proportion of 
deaths were also summarized for each exposure group.   
Inverse probability of treatment (IPT) weights were computed to adjust for confounding 
between CR initiation and subsequent cardiovascular hospitalization after index MI.  The logistic 
regression model used to estimate the probability of initiating CR contained a variety of baseline 
variables identified as potential confounders from subject matter knowledge encoded in directed 
acyclic graphs (Appendix Table 6).  A small subset of these variables were removed from the 
final model to allow for model convergence.  Age and length of hospital stay (LOS) were 
included in the models as restricted cubic splines with 3 and 4 knots respectively [82].  The 
distribution of the predicted probabilities from the final logistic regression model was examined 
for overlap between exposure groups. The final weights used in the analysis of outcomes were 
calculated by taking the inverse of the probability of treatment conditional on measured 
covariates stabilized by multiplying by the unconditional probability of treatment (shown below).   
𝑃𝑇𝑊𝑖 =  
Pr (𝐶𝑅 = 𝑥)
Pr(𝐶𝑅 = 𝑥 | 𝒁)
  
The unconditional probability in the numerator is used to reduce the variability in the weights 
[83].  The same IPT weights were used in the analysis of all study outcomes. In a sensitivity 
analysis, conditions defined by Elixhauser et.al were used to model comorbidity instead of the 
Gagne score in computing IPT weights [80].   Standardized differences were calculated to detect 
differences between CR initiators and non-initiators in IPT weighted populations.   
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Cumulative incidence of each outcome was estimated using non-parametric cumulative 
incidence estimators with death treated as a competing event [84]. Cumulative incidence curves 
for each hospital outcome and the corresponding competing event of death were produced for 
each outcome separately.  The 1-year risk difference and risk ratio between CR initiators and 
non-initiators were computed from cumulative incidence estimates with and without IPT weight 
adjustment separately.  The 1-year risk difference calculated from IPT weighted cumulative 
incidence estimators represents the population average treatment effect [85]. We conducted 
stratified analyses by age group (65 – 74 and 75 – 84 years old), mortality risk (Gagne score 
<five or ≥5), and exposure period GRM use (0, 1-2, and 3-4).  High mortality risk defined as ≥ 
17% chance of death within 1 year by Gagne et al. corresponded to scores ≥5.  Gray’s test was 
used to test for differences between groups in the stratified analysis [86].  All analyses were 
completed using SAS 9.4. 
 
3. Results. 
We identified 32, 851 beneficiaries who met study criteria.  The majority of study 
participants were male (52.1%), White (88.4%), and the mean age at index MI was 75 (SD 6.0) 
years old.  Cardiac rehabilitation (CR) was initiated differently across several key baseline 
characteristics such as demographic minority, type of revascularization procedure performed 
during index hospitalizations, and mean comorbidity score (Table 5.1:).  By applying stabilized 
inverse probability of treatment weights, we were able to eliminate the large measured 
imbalances between exposure groups.  The variables used in the final IPT weighting model 
included demographic characteristics, baseline conditions, index hospitalization care, and 
medication use. 
 51 
Only 21% of study participants initiated CR during the exposure period.  Initiators 
participated in an average of 10.6 sessions during the exposure period.  In the weighted 
population, CR initiators contributed 9,758 person years of follow-up time for MI hospitalization 
outcome and had an observed mortality rate of 2.1 beneficiaries per 100 person years while CR 
non-initiators contributed 35,672 person years of follow-up time and had an observed mortality 
rate of 3.5 beneficiaries per 100 person years (data not shown).  The observed mortality rate was 
lower in the CR initiator group than in the non-initiator group for all outcomes studied (Table 
5.2:). As expected, there were more all-cause admission events than MACE events than MI 
events. 
Plots of the cumulative incidence during follow-up (Figure 5.2) reveal that CR initiators had 
a lower risk of hospitalization (top row) and competing death event (bottom row) than non-
initiators even at 90-days post discharge (30 days of follow-up).   While the risk of MI 
hospitalization was similar in scale to the competing risk of all-cause death in this study, the risk 
of MI admission was slightly higher than the risk of death during follow-up.  Confounding 
adjustment by IPT weighting attenuated differences between exposure groups for MI 
hospitalization and death events (Table 5.2:). Side by side depiction of adjusted cumulative 
incidence curves for MI, MACE, and all-cause admission illustrate only a small difference 
between CR initiators and non-initiators for each of these outcomes (Figure 5.2). This small 
difference persisted for all three outcomes during follow-up.  At 1-year post discharge there was 
a less than 3% absolute risk reduction in MI (1.0%), MACE (2.4%), and all-cause (2.8%) 
hospitalizations among CR initiators when compared to non-initiators (Table 5.2:) after adjusting 
for confounding and the competing risk of death.  The small absolute differences had 
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corresponding risk ratios of 0.81 (0.70, 0.92), 0.87 (0.81, 0.93), and 0.92 (0.89, 0.95) for MI, 
MACE, and all-cause hospitalization respectively. 
We also investigated if there was difference between exposure groups in the risk of each 
outcome by age group, Gagne score, and exposure period GRM use (Table 5.3:).  The negative 
absolute 1-year risk difference between CR initiators and non-initiators for recurrent MI was 
similar for each age group.  For the all-cause admission outcome, beneficiaries in the older age 
group had a larger 1-year risk reduction than younger age group.  Beneficiaries with a Gagne 
score ≥5 had approximately 2.5 times the 1-year risk of experiencing study cardiovascular 
outcomes than beneficiaries with a Gagne score < 5.  A negative risk difference between CR 
initiators and non-initiators was observed for all study outcomes among beneficiaries with a 
Gagne score < 5 but not the higher Gagne score group.   Beneficiaries who had days supply for 
1-2 GRMs at day 60 had an insignificant <1% decrease in the 1-year risk of MI between CR 
initiators and non-initiators but at least a 2% decrease in the 1-year risk of MACE or all-cause 
admission outcomes.  Beneficiaries who had days supply for 3-4 GRMs at day 60 had the highest 
risk reduction of hospital admission in the GRM stratified analyses regardless of outcome.  The 
sensitivity analysis using the Elixhauser definitions of comorbid conditions produced estimates 
that were slightly closer to the null than the main analysis but did not change our conclusions 
(data not shown).  
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4. Discussion 
We examined the association between CR initiation and re-hospitalization following an index 
MI among older adults.  The observed low CR initiation was similar to what has been reported in 
an earlier study of Medicare beneficiaries with an index MI occurring in 1997 (24%) and was 
lower than estimates reported by a more recent registry study (32%) [20, 79]. A small difference 
in absolute measures of 1-year risk of recurrent MI between CR initiators and non-initiators 
translated into a large relative difference due to the low risk in each group. The observed relative 
risk of recurrent MI within 1 year of discharge of 0.81 (95% CI 0.70, 0.92) was similar to results 
reported in a meta-analysis of CR clinical trials by Clark et al. (0.83 95% CI 0.74, 0.94) [4]. The 
low (<10%) 1-year risk of recurrent MI reported in this study is consistent with a recent 
randomized clinical trial by West et al. of CR use after MI [78].  While Clark et al reported a 
statistical difference in recurrent MI between rehabilitation users and controls; West et al 
concluded there was no difference in risk of recurrent MI between CR users and controls. Based 
upon the results of this study, we conclude that the small effect that CR has on the 1-year risk of 
recurrent MI does not have the same public health importance as the effect of CR on the other 
hospitalization outcomes investigated in this study. 
The 1-year risk of MACE admission and all-cause hospitalization was 4 to 7 times greater 
than the 1-year risk of MI readmission in this study.   While the magnitude of the 1-year risk 
difference was similar between the MACE and all-cause hospitalization outcomes, the relative 
measure of the difference between CR initiator and non-initiators was different due to difference 
in the baseline risk of each outcome.  In a study of CR participation between 1987 and 2010 of 
Olmsted County residents, Dunlay et al reported a 20% and 25% decrease in the relative risk of 
cardiovascular admission and all-cause hospitalization respectively between initiators and non-
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initiators [87].  The average follow-up time in the Dunlay study was 7.6 years [87].  With a 1-
year hazard ratio of 0.85 (95% CI: 0.79 to 0.91) for MACE admissions, our study supports that a 
majority of the benefit of CR on cardiovascular admission in MI survivors occurs within the first 
year of discharge.  Similarly, we observed evidence of a decrease in the all-cause admissions, 1-
year hazard ratio 0.89 (95%CI: 0.84 to 0.94) but not to the same degree as results reported by 
Dunlay et al., hazard ratio of 0.75 (95%CI: 0.65 to 0.87).  
Stratified analysis in our study showed that older beneficiaries (>75 years olda0 had a greater 
reduction in the all-cause admission outcome than the cardiovascular outcomes.  In addition, 
those CR initiators with days supply of 3-4 GRMs at day 60 had a lower 1-year risk of each 
hospitalization outcome than CR initiators with days supply of less medication at day 60.  The 
former observation supports an AHA scientific statement that encourages the use of secondary 
prevention methods in elderly patients especially those at least 75 years old [88].  The latter 
observation represents an opportunity for public health intervention since CR participation has 
also been shown to increase medication adherence [79]. It should also be noted that the risk of 
each study outcome for CR initiators with days supply of 1-2 medications at day 60 is similar to 
the risk of that same outcome in CR non-initiators with days supply of 3-4 medications at day 60. 
We decided to restrict our study population to beneficiaries who received a revascularization 
procedure during their index hospitalizations for several reasons.  First, previous literature has 
reported that revascularization is highly associated with referral for CR [23]; therefore, 
restriction may impose a level of homogeneity of treatment groups that should reduce indication 
bias. Since we cannot measure which of the non-initiators were also not referred for CR, this 
restriction eliminates from our risk set a pool of patients who would never initiate because they 
were never referred.  This is not a perfect proxy for referral since we are also removing patients 
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from our population that were referred.  However, this restriction is an imperfect measure of 
referral and limits the generalizability of our results.  
Conducting research using administrative claims data has both limitations and benefits.  First, 
administrative claims data were created for financial purposes not research purposes.  While 
there is some overlap in these objectives, research relevant details are absent from claims data 
where these objectives begin to diverge.  For example, clinical data such as laboratory results, 
smoking status, and BMI are lacking in administrative data.  In this study, we attempted to 
overcome the presence of this unmeasured confounding using propensity score techniques but 
realize that residual confounding may still exist in our results. The lack of an association between 
CR initiation and fracture risk (the negative control outcome) suggested that our study results 
may not be subject to substantial residual confounding. 
We were limited to claims for beneficiaries who were continuously enrolled in Medicare Part 
D and Medicare Part A and B from 1 year before their index hospitalization until December 31, 
2009 or death. By restricting to the continuously covered population, we may be limiting the 
generalizability of our study findings; however, the size and nature of the population is still of 
public health importance.    There was the potential for misclassification of exposure to GRMs 
due to use of over the counter aspirin, free medication samples risk [75] and purchase of 
prescription drugs without filing an insurance claim [74].  Besides over-the-counter aspirin use, 
generic options of the medication classes included in this study were offered at prices low 
enough to be regularly purchased using cash without filing a claim.  These cash transactions 
were not captured in our study data.  However, we expect the use of these medications to be non-
differential with respect to the use of cardiac rehabilitation services.   
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There are several strengths to this study.  Our claims-based analysis is not subject to recall 
bias since we have documentation on the receipt and timing of health services studied. While 
filling a prescription does not guarantee that the medication has been taken, it is likely a better 
measure of medication exposure than definitions by prescriptions written at discharge.  Most of 
the clinical trials of cardiac rehabilitation were small (<300 enrollees) enrolling younger (under 
the age of 60) predominately male populations, conducted before improvements in secondary 
prevention medications, and conducted in countries outside the US where access to care is 
different [77].  The larger sample size than clinical trials, the inclusion of large percentage of 
women, and focusing on older adults are advantages to this study. 
In conclusion, our results suggest that outpatient cardiac rehabilitation may reduce 
cardiovascular and all-cause hospital admissions 1-year post discharge in elderly MI survivors.  
However, public health interventions are need to improve the observed low rates of CR initiation 
among older adults for these benefits to be fully realized in elderly MI survivors.   
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5. Tables. 
Table 5.1: Study Population Characteristics 
 Unadjusted  
IPT  
Weighted 
 
CR Non-
Initiators 
CR 
Initiators 
Standardized 
Difference  
Standardized 
Difference 
Overall 25,935 6,916    
Demographics      
   Mean Age (SD) 75.1 ( 5.98) 74.2 ( 5.58) -0.157  0.001 
   Female 12,788 (49.3%) 2,933 (42.4%) -0.139  -0.013 
   Minority 3,473 (13.4%) 346 ( 5.0%) -0.293  0.038 
Index Hospitalizations      
   Revascularization      
      Angioplasty 21,358 (82.4%) 5,101 (73.8%) -0.209  -0.007 
      CABG 4,741 (18.3%) 2,004 (29.0%) 0.254  0.015 
      Stent 19,539 (75.3%) 4,690 (67.8%) -0.167  -0.011 
   Cardiogenic Shock 1,213 ( 4.7%) 318 ( 4.6%) -0.004  0.005 
   Any ICU Stay 15,477 (59.7%) 4,265 (61.7%) 0.041  0.009 
   Any CCU Stay 12,311 (47.5%) 3,374 (48.8%) 0.026  0.007 
   Hospital Transfer Group      
       0 19,605 (75.6%) 5,725 (82.8%) 0.178  0.003 
       1 5,080 (19.6%) 1,026 (14.8%) -0.126  0.001 
       >2 1,250 ( 4.8%) 165 ( 2.4%) -0.131  -0.008 
Baseline Medications      
Any Baseline 
Coverage Gap      
      Doughnut Hole 7,601 (29.3%) 1,421 (20.5%) -0.204  0.010 
Baseline Comorbidities      
Gagne Comorbidity 
Score      
      Mean (SD) 1.7 ( 2.22) 1.0 ( 1.79) -0.322  0.015 
   Comorbid Conditions      
      Hyperlipidemia 18,509 (71.4%) 5,275 (76.3%) 0.112  -0.007 
Osteoporosis or 
Osteoarthritis 6,319 (24.4%) 1,656 (23.9%) -0.010  0.005 
      Hypotension 2,218 ( 8.6%) 562 ( 8.1%) -0.015  -0.007 
      Hypertension 21,664 (83.5%) 5,486 (79.3%) -0.108  -0.002 
Uncomplicated 
Diabetes 10,727 (41.4%) 2,271 (32.8%) -0.177  0.013 
Congestive Heart 
Failure 8,947 (34.5%) 1,629 (23.6%) -0.243  -0.007 
      Cardiac Arrhythmia 7,992 (30.8%) 2,007 (29.0%) -0.039  0.035 
Chronic Pulmonary 
Disease 7,844 (30.2%) 1,481 (21.4%) -0.203  0.018 
Peripheral Vascular 
Disease 5,449 (21.0%) 960 (13.9%) -0.189  0.025 
      Valvular Disease 4,756 (18.3%) 1,153 (16.7%) -0.044  -0.011 
      Complicated Diabetes 3,147 (12.1%) 502 ( 7.3%) -0.165  0.013 
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 Unadjusted  
IPT  
Weighted 
 
CR Non-
Initiators 
CR 
Initiators 
Standardized 
Difference  
Standardized 
Difference 
      Cancer 2,745 (10.6%) 753 (10.9%) 0.010  0.007 
Cerebrovascular 
Disease 2,588 (10.0%) 471 ( 6.8%) -0.114  -0.011 
      Rheumatic Disease 1,242 ( 4.8%) 326 ( 4.7%) -0.004  0.006 
      Renal Disease 1,210 ( 4.7%) 139 ( 2.0%) -0.148  0.017 
      Metastatic Carcinoma 294 ( 1.1%) 49 ( 0.7%) -0.045  -0.011 
Day 60 Medication      
   GRM Group      
      0 1,651 ( 6.4%) 235 ( 3.4%) -0.138  -0.046 
      1-2 7,695 (29.7%) 1,896 (27.4%) -0.050  0.017 
      3-4 16,589 (64.0%) 4,785 (69.2%) 0.111  0.005 
Note: IPT – Inverse Probability of Treatment Weighted.  CR – Outpatient Cardiac Rehabilitation. 
SD – Standard Deviation. CABG – Coronary Artery Bypass Grafting. ICU – Intensive Care Unit. 
CCU – Cardiac Care Unit. GRM – Guideline Recommended Medications. 
  
 
Table 5.2: Summary of Person-Time on Study, Risk, Risk Difference, and Relative Risk of Study Outcomes at 1-Year Post-MI for 
Outpatient Cardiac Rehabilitation (CR) Initiators verses Non-Initiators 
Outcome 
Cardiac 
Rehab 
Person 
years 
(PY) Events Deaths 
Mortality 
Rate 
(/100 PY) 
Unadjusted  
Risk (%) 
Unadjusted 
Risk 
Difference 
Adjusted  
Risk (%) 
Adjusted 
Risk 
Difference 
Adjusted 
Risk Ratio 
MI 
Non-
Initiators 35,353.51 1,900 1,362 3.9 
5.6 
( 5.3,  5.9)  
5.2 
( 5.0,  5.5)   
  Initiators 9,960.09 250 127 1.3 
2.7 
( 2.3,  3.1) 
-2.9 
( -3.0,  -2.8) 
4.2 
( 3.5,  5.1) 
-1.0 
( -1.5,  -0.4) 
0.81 
( 0.70,  0.92) 
MACE 
Non-
Initiators 28,638.04 5,591 958 3.3 
19.2 
(18.7, 19.8)  
18.0 
(17.6, 18.4)   
  Initiators 8,807.76 960 109 1.2 
11.7 
(10.9, 12.5) 
-7.5 
( -7.8,  -7.3) 
15.7 
(14.3, 17.2) 
-2.4 
( -3.3,  -1.2) 
0.87 
( 0.81,  0.93) 
All-Cause 
Admission 
Non-
Initiators 21,466.26 8,462 725 3.4 
34.6 
(33.9, 35.4)  
33.2 
(32.5, 33.8)   
  Initiators 7,020.35 1,947 92 1.3 
26.0 
(24.9, 27.2) 
-8.6 
( -9.0,  -8.1) 
30.4 
(28.8, 32.1) 
-2.8 
( -3.7,  -1.7) 
0.92 
( 0.89,  0.95) 
Fracture 
Non-
Initiators 36,915.43 804 1,466 4.0 
2.1 
( 2.0,  2.3)  
2.0 
( 1.8,  2.1)   
  Initiators 10,168.98 142 136 1.3 
1.4 
( 1.1,  1.7) 
-0.8 
( -0.9,  -0.6) 
1.9 
( 1.4,  2.4) 
-0.1 
( -0.4,   0.3) 
0.94 
( 0.78,  1.15) 
Note: MI – Myocardial Infarction. MACE - major adverse cardiovascular and cerebrovascular event (MI, angina, heart failure, or stroke) 
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Table 5.3: Stratified Analysis of Risk, Risk Difference, and Relative Risk of Study Outcomes at 
1-Year Post-MI for Outpatient Cardiac Rehabilitation (CR) Initiators verses Non-Initiators 
 
CR Non-
Initiators 
Risk (%) 
CR Initiators 
Risk (%) 
Risk  
Difference 
Risk 
Ratio 
MI     
Age Group     
  Age 65-74 years 4.6 ( 4.2,  5.0) 3.7 ( 2.8,  4.9) -0.8 ( -1.4,  -0.0) 0.8 ( 0.66,  1.00) 
  Age 75-84 years 5.8 ( 5.4,  6.2) 4.7 ( 3.4,  6.2) -1.1 ( -2.1,  -0.0) 0.8 ( 0.62,  0.99) 
Morbidity Risk     
  Gagne Score < 5 4.7 ( 4.4,  5.0) 3.5 ( 2.8,  4.1) -1.2 ( -1.6,  -0.8) 0.7 ( 0.64,  0.83) 
  Gagne Score >=5 10.6 ( 9.5, 11.9) 11.2 ( 6.2, 17.1) 0.6 ( -3.3,   5.3) 1.1 ( 0.65,  1.44) 
Day 60 GRM 
Group     
  0 5.2 ( 4.1,  6.3) 7.0 ( 1.3, 15.3) 1.8 ( -2.8,   9.0) 1.3 ( 0.33,  2.43) 
  1-2 5.7 ( 5.2,  6.2) 4.8 ( 3.0,  6.5) -0.9 ( -2.1,   0.3) 0.8 ( 0.59,  1.05) 
  3-4 5.0 ( 4.7,  5.4) 3.8 ( 2.9,  4.5) -1.3 ( -1.8,  -0.9) 0.8 ( 0.62,  0.84) 
MACE     
Age Group     
  Age 65-74 years 15.4 (14.8, 16.0) 13.6 (12.0, 15.4) -1.8 ( -2.8,  -0.6) 0.9 ( 0.81,  0.96) 
  Age 75-84 years 20.0 (19.2, 20.9) 18.0 (15.6, 21.3) -2.0 ( -3.6,   0.4) 0.9 ( 0.81,  1.02) 
Morbidity Risk     
  Gagne Score < 5 16.3 (15.8, 16.8) 13.5 (12.6, 14.7) -2.7 ( -3.2,  -2.1) 0.8 ( 0.80,  0.88) 
  Gagne Score >=5 37.9 (35.9, 39.9) 36.1 (26.4, 45.7) -1.7 ( -9.5,   5.8) 1.0 ( 0.74,  1.15) 
Day 60 GRM 
Group     
  0 20.0 (18.0, 22.0) 21.5 (12.8, 30.7) 1.5 ( -5.1,   8.7) 1.1 ( 0.71,  1.40) 
  1-2 19.1 (18.1, 19.9) 17.1 (14.7, 19.6) -2.0 ( -3.4,  -0.3) 0.9 ( 0.81,  0.98) 
  3-4 17.4 (16.8, 18.0) 14.6 (12.7, 16.5) -2.8 ( -4.1,  -1.5) 0.8 ( 0.76,  0.92) 
All-Cause 
Admission     
Age Group     
  Age 65-74 years 29.9 (29.0, 30.9) 28.7 (26.7, 31.3) -1.2 ( -2.3,   0.4) 1.0 ( 0.92,  1.01) 
  Age 75-84 years 35.7 (34.6, 36.6) 32.6 (28.9, 35.4) -3.0 ( -5.7,  -1.2) 0.9 ( 0.84,  0.97) 
Morbidity Risk     
  Gagne Score < 5 31.3 (30.7, 31.9) 27.7 (26.0, 28.9) -3.6 ( -4.7,  -3.0) 0.9 ( 0.85,  0.91) 
  Gagne Score >=5 56.6 (54.0, 58.8) 57.0 (46.9, 65.8) 0.4 ( -7.1,   7.0) 1.0 ( 0.87,  1.12) 
Day 60 GRM 
Group     
  0 33.0 (30.1, 36.0) 39.7 (28.5, 51.4) 6.7 ( -1.6,  15.4) 1.2 ( 0.95,  1.43) 
  1-2 34.1 (32.5, 35.4) 31.8 (28.4, 35.0) -2.3 ( -4.1,  -0.4) 0.9 ( 0.87,  0.99) 
  3-4 32.8 (32.0, 33.6) 29.1 (26.8, 31.1) -3.7 ( -5.2,  -2.5) 0.9 ( 0.84,  0.93) 
Note: MI – Myocardial Infarction. MACE – major adverse cardiovascular and cerebrovascular 
event (MI, angina, heart failure, or stroke). GRM Guideline Recommended Medications. 
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6. Figures 
Figure 5.1: Study Design 
 
 
Figure 5.2: Inverse Probability of Treatment Weighted Cumulative Incidence of All Study 
Outcomes and Competing Risk of Death in Outpatient Cardiac Rehabilitation Initiators 
compared to Non-Initiators 
 
Note: MACE - major adverse cardiovascular and cerebrovascular event (MI, angina, heart 
failure, or stroke 
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CHAPTER 6: CONCLUSIONS AND PUBLIC HEALTH IMPACT 
The intent of this dissertation was to investigate the use of secondary prevention guideline 
recommendations among Medicare beneficiaries.  This was accomplished in two steps. First, the 
initiation of cardiac rehabilitation and the concurrent use of guideline recommended medications 
after an index myocardial infarction were summarized in the comparison of methods to account 
for death before the outcome of interest when conducting survival data analysis.  This manuscript 
described the less than optimal adoption of guideline recommendations.  By 1-year post-MI 
discharge, beneficiaries were more likely to fill prescriptions for concordant guideline 
medications (51.4%) than participate in cardiac rehabilitation (14.2%) before death.  In addition, 
the proportion of CR initiators nearly doubled between 30 days post discharge and 90 days post 
discharge.  This result has implications for outcomes research with CR initiation as an exposure 
when employing fixed exposure windows in the design.  Restricting the study cohort by survival 
reduced the population at risk while censoring by death assumed that patients who die could still 
go on to participate with therapy.  These methods of accounting for death resulted in higher 
estimates of post-MI CR and GRM use then competing risk estimates.  In studies where 
mortality is more common, restricting the study to patients who survive may affect 
generalizability and may introduce some survivor bias in the results.  In these settings, competing 
risk approaches would be preferable.  Because clinical trials and observational studies provided 
as support for guideline recommendations focused on the efficacy of each component 
individually, this study adds to existing knowledge by summarizing exposure to multiple 
guideline components after index hospitalization discharge. 
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The second manuscript summarized the relationship between initiation of cardiac 
rehabilitation and hospital admission following an index MI among older adults having a 
revascularization procedure. The 1-year risk of cardiovascular or all-cause hospitalization was 4 
to 7 times greater than the 1-year risk of MI readmission in this study.   The risk difference 
between CR initiators and non-initiators for cardiovascular and all-cause hospitalization 
outcomes following an index MI were small but clinically significant. In the stratified analysis, 
marginally greater benefit of CR initiation on these outcomes was observed in beneficiaries that 
were older (75 to 85 years old), healthier (Gagne score <5), and more compliant with guideline 
medications (at least 1) compared to beneficiaries 65 to 74, Gagne score ≥ 5, or not taking any 
guideline recommended medication respectively. 
By investigating use of both health care services and evidence based medications using 
competing risks methods of survival data analysis, this dissertation adds to the knowledge 
regarding the use of secondary prevention methods in an elderly US population. The size and 
nature of the population involved in this investigation is of public health importance since 
previous studies of secondary prevention methods focused on younger male patients and may 
have overestimated the effects of these recommendations on non-fatal outcomes when death was 
not properly analyzed.   Results from this dissertation support that outpatient cardiac 
rehabilitation reduces cardiovascular and all-cause hospital admissions 1-year post discharge in 
elderly MI survivors.  However, the potential benefit to society from using this therapy is not 
fully realized due to the observed low adoption of guideline recommendations among Medicare 
beneficiaries.  Results from this dissertation can be used in public health interventions to inform 
patients and practitioners of the benefits of following guideline recommendations and encourage 
referral and participation in cardiac rehabilitation among older adult MI survivors. 
 †Non-HDL-C = total cholesterol minus HDL-C.  ‡Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury. 
§When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C <70 mg/dL is the chosen target, consider drug titration to achieve 
this level to minimize side effects and cost. When LDL-C <70 mg/dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of 
>50% in LDL-C levels by either statins or LDL-C–lowering drug combinations. 
¶The combination of high-dose statin fibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. Dietary supplement niacin 
must not be used as a substitute for prescription niacin. 
#Patients with very high triglycerides should not consume alcohol. The use of bile acid sequestrant is relatively contraindicated when triglycerides are >200 mg/dL. 
Standard dose of statin with ezetimibe, bile acid sequestrant, or niacin. **Creatinine should be <2.5 mg/dL in men and <2.0 mg/dL in women.  ††Potassium should be <5.0 
mEq/L. 
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APPENDIX 
Appendix Table 1: Summary of secondary prevention guideline recommendations ([10, 11]) 
Component Intervention Recommendation Class 
NUTRITION 
COUNSELING 
AND WEIGHT 
MANAGEMENT 
Goal: 
Body mass index: 
18.5 to 24.9 kg/m2 
Waist 
circumference: men 
<40 inches, Women 
<35 inches 
 
 Assess body mass index and/or waist circumference on each visit and consistently encourage weight 
maintenance/reduction through an appropriate balance of physical activity, caloric intake, and formal 
behavioral programs when indicated to maintain/achieve a body mass index between 18.5 and 24.9 
kg/m2.  
 If waist circumference (measured horizontally at the iliac crest) is ≥35 inches in women and ≥40 inches 
in men, initiate lifestyle changes and consider treatment strategies for metabolic syndrome as indicated.  
 The initial goal of weight loss therapy should be to reduce body weight by approximately 10% from 
baseline. With success, further weight loss can be attempted if indicated through further assessment. 
 
I (B) 
I (B) 
I (B) 
 
DIABETES 
MANAGEMENT 
Goal: 
HbA1c <7% 
 
 
 Initiate lifestyle and pharmacotherapy to achieve near-normal HbA1c. 
 Begin vigorous modification of other risk factors (e.g., physical activity, weight management, blood 
pressure control, and cholesterol management as recommended above).  
 Coordinate diabetic care with patient’s primary care physician or endocrinologist. 
 
I (B) 
I (B) 
I (C) 
 
 †Non-HDL-C = total cholesterol minus HDL-C.  ‡Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury. 
§When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C <70 mg/dL is the chosen target, consider drug titration to achieve 
this level to minimize side effects and cost. When LDL-C <70 mg/dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of 
>50% in LDL-C levels by either statins or LDL-C–lowering drug combinations. 
¶The combination of high-dose statin fibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. Dietary supplement niacin 
must not be used as a substitute for prescription niacin. 
#Patients with very high triglycerides should not consume alcohol. The use of bile acid sequestrant is relatively contraindicated when triglycerides are >200 mg/dL. 
Standard dose of statin with ezetimibe, bile acid sequestrant, or niacin. **Creatinine should be <2.5 mg/dL in men and <2.0 mg/dL in women.  ††Potassium should be <5.0 
mEq/L. 
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Component Intervention Recommendation Class 
BLOOD 
PRESSURE 
CONTROL 
Goal:   
<140/90 mm Hg or 
<130/80 mm Hg if 
patient has diabetes 
or chronic kidney 
disease 
For all patients: 
 Initiate or maintain lifestyle modification—weight control; increased physical activity; alcohol 
moderation; sodium reduction; and emphasis on increased consumption of fresh fruits, vegetables, and 
low-fat dairy products 
For patients with blood pressure >140/90 mm Hg (or >130/80 mm Hg for individuals with diabetes or 
chronic kidney disease): 
 As tolerated, add blood pressure medication, treating initially with ß-blockers and/or ACE inhibitors, 
with addition of other drugs such as thiazides as needed to achieve goal blood pressure 
[For compelling indications for individual drug classes in specific vascular diseases, see Seventh Report of 
the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
(JNC 7)] 
 
 
I (B) 
 
 
I (A) 
 
 †Non-HDL-C = total cholesterol minus HDL-C.  ‡Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury. 
§When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C <70 mg/dL is the chosen target, consider drug titration to achieve 
this level to minimize side effects and cost. When LDL-C <70 mg/dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of 
>50% in LDL-C levels by either statins or LDL-C–lowering drug combinations. 
¶The combination of high-dose statin fibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. Dietary supplement niacin 
must not be used as a substitute for prescription niacin. 
#Patients with very high triglycerides should not consume alcohol. The use of bile acid sequestrant is relatively contraindicated when triglycerides are >200 mg/dL. 
Standard dose of statin with ezetimibe, bile acid sequestrant, or niacin. **Creatinine should be <2.5 mg/dL in men and <2.0 mg/dL in women.  ††Potassium should be <5.0 
mEq/L. 
6
6
 
Component Intervention Recommendation Class 
SMOKING 
CESSATION 
COUNSELING 
Goal:   
Complete cessation.  
No exposure to 
environmental 
tobacco smoke. 
 
 Ask about tobacco use status at every visit 
 Advise every tobacco user to quit 
 Assess the tobacco user’s willingness to quit 
 Assist by counseling and developing a plan for quitting 
 Arrange follow-up, referral to special programs, or pharmacotherapy (including nicotine replacement 
and bupropion) 
 Urge avoidance of exposure to environmental tobacco smoke at work and home 
 
I (B) 
I (B) 
I (B) 
I (B) 
I (B) 
I (B) 
 
 
LIPID 
MANAGEMENT 
Goal:  
LDL-C <100 
mg/dL  
If triglycerides are 
≥200 mg/dL, non-
HDL-C should be 
<130 mg/dL† 
For all patients: 
 Reduce intake of saturated fats (to <7% of total calories), trans-fatty acids, and cholesterol (to <200 
mg/d). 
 Adding plant stanol/sterols (2 g/d) and viscous fiber (>10 g/d) will further lower LDL-C 
 Promote daily physical activity and weight management 
 Encourage increased consumption of omega-3 fatty acids in the form of fish‡ or in capsule form (1 g/d) 
for risk reduction.  For treatment of elevated triglycerides, higher doses are usually necessary for risk 
reduction. 
 
 
I (B) 
 
I (B) 
IIb (B) 
 
 †Non-HDL-C = total cholesterol minus HDL-C.  ‡Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury. 
§When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C <70 mg/dL is the chosen target, consider drug titration to achieve 
this level to minimize side effects and cost. When LDL-C <70 mg/dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of 
>50% in LDL-C levels by either statins or LDL-C–lowering drug combinations. 
¶The combination of high-dose statin fibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. Dietary supplement niacin 
must not be used as a substitute for prescription niacin. 
#Patients with very high triglycerides should not consume alcohol. The use of bile acid sequestrant is relatively contraindicated when triglycerides are >200 mg/dL. 
Standard dose of statin with ezetimibe, bile acid sequestrant, or niacin. **Creatinine should be <2.5 mg/dL in men and <2.0 mg/dL in women.  ††Potassium should be <5.0 
mEq/L. 
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Component Intervention Recommendation Class 
LIPID 
MANAGEMENT 
Goal:  
LDL-C <100 
mg/dL  
If triglycerides are 
≥200 mg/dL, non-
HDL-C should be 
<130 mg/dL† 
 
For lipid management: 
Assess fasting lipid profile in all patients, and within 24 hours of hospitalization for those with an acute 
cardiovascular or coronary event. For hospitalized patients, initiate lipid-lowering medication as 
recommended below before discharge according to the following schedule 
 LDL-C should be <100 mg/dL and 
 Further reduction of LDL-C to <70 mg/dL is reasonable 
 If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy § 
 If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-
lowering drug combination) 
 If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL 
 If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL, and 
 Further reduction of non-HDL-C to <100 mg/dL is reasonable 
 Therapeutic options to reduce non-HDL-C are: 
o More intense LDL-C–lowering therapy or 
o Niacin¶ (after LDL-C–lowering therapy) or Fibrate therapy# (after LDL-C–lowering therapy) 
 If triglycerides are 500 mg/dL#, therapeutic options to prevent pancreatitis are fibrate¶ or niacin¶ before 
LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy.  Achieve non-HDL-
C <130 mg/dL if possible.  
 
 
I (A) 
IIa (A) 
I (A) 
I (A) 
IIa (B) 
I (B) 
IIa (B) 
 
I (B) 
IIa (B) 
I (C) 
 
 †Non-HDL-C = total cholesterol minus HDL-C.  ‡Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury. 
§When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C <70 mg/dL is the chosen target, consider drug titration to achieve 
this level to minimize side effects and cost. When LDL-C <70 mg/dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of 
>50% in LDL-C levels by either statins or LDL-C–lowering drug combinations. 
¶The combination of high-dose statin fibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. Dietary supplement niacin 
must not be used as a substitute for prescription niacin. 
#Patients with very high triglycerides should not consume alcohol. The use of bile acid sequestrant is relatively contraindicated when triglycerides are >200 mg/dL. 
Standard dose of statin with ezetimibe, bile acid sequestrant, or niacin. **Creatinine should be <2.5 mg/dL in men and <2.0 mg/dL in women.  ††Potassium should be <5.0 
mEq/L. 
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Component Intervention Recommendation Class 
ß-BLOCKERS  Start and continue indefinitely in all patients who have had myocardial infarction, acute coronary 
syndrome, or left ventricular dysfunction with or without heart failure symptoms, unless contraindicated 
 Consider chronic therapy for all other patients with coronary or other vascular disease or diabetes unless 
contraindicated 
 
I (A) 
IIa (C) 
 
RENIN-
ANGIOTENSIN-
ALDOSTERONE 
SYSTEM 
BLOCKERS 
 
ACE inhibitors: 
 Start and continue indefinitely in all patients with left ventricular ejection fraction  ≤ 40% and in those 
with hypertension, diabetes, or chronic kidney disease, unless contraindicated 
 Consider for all other patients 
 Among lower-risk patients with normal left ventricular ejection fraction in whom cardiovascular risk 
factors are well controlled and revascularization has been performed, use of ACE inhibitors may be 
considered optional 
Angiotensin receptor blockers: 
 Use in patients who are intolerant of ACE inhibitors and have heart failure or have had a myocardial 
infarction with left ventricular ejection fraction ≤ 40% 
 Consider in other patients who are ACE inhibitor intolerant 
 Consider use in combination with ACE inhibitors in systolic-dysfunction heart failure 
Aldosterone blockade: 
 Use in post–myocardial infarction patients, without significant renal dysfunction** or hyperkalemia††, 
who are already receiving therapeutic doses of an ACE inhibitor and ß-blocker, have a left ventricular 
ejection fraction ≤ 40%, and have either diabetes or heart failure 
 
 
 I (A) 
I (B) 
IIa (B) 
 
I (A) 
I (B) 
IIb (B) 
 
I (A) 
 
 †Non-HDL-C = total cholesterol minus HDL-C.  ‡Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury. 
§When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C <70 mg/dL is the chosen target, consider drug titration to achieve 
this level to minimize side effects and cost. When LDL-C <70 mg/dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of 
>50% in LDL-C levels by either statins or LDL-C–lowering drug combinations. 
¶The combination of high-dose statin fibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. Dietary supplement niacin 
must not be used as a substitute for prescription niacin. 
#Patients with very high triglycerides should not consume alcohol. The use of bile acid sequestrant is relatively contraindicated when triglycerides are >200 mg/dL. 
Standard dose of statin with ezetimibe, bile acid sequestrant, or niacin. **Creatinine should be <2.5 mg/dL in men and <2.0 mg/dL in women.  ††Potassium should be <5.0 
mEq/L. 
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Component Intervention Recommendation Class 
ANTIPLATELET 
AGENTS/ ANTI-
COAGULANTS 
 
 Start aspirin 75 to 162 mg/d and continue indefinitely in all patients unless contraindicated 
o For patients undergoing coronary artery bypass grafting, aspirin should be started within 48 hours 
after surgery to reduce saphenous vein graft closure.  Dosing regimens ranging from 100 to 325 
mg/d appear to be efficacious.  Doses higher than 162 mg/d can be continued for up to 1 year. 
 Start and continue clopidogrel 75 mg/d in combination with aspirin for up to 12 months in patients after 
acute coronary syndrome or percutaneous coronary intervention with stent placement (≥1 month for bare 
metal stent,  ≥3 months for sirolimus-eluting stent, and  ≥6 months for paclitaxel-eluting stent) 
o Patients who have undergone percutaneous coronary intervention with stent placement should 
initially receive higher-dose aspirin at 325 mg/d for 1 month for bare metal stent, 3 months for 
sirolimus-eluting stent, and 6 months for paclitaxel-eluting stent. 
 Manage warfarin to international normalized ratio=2.0 to 3.0 for paroxysmal or chronic atrial fibrillation 
or flutter, and in post–myocardial infarction patients when clinically indicated (e.g., atrial fibrillation, 
left ventricular thrombus). 
 Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with increased risk of 
bleeding and should be monitored closely. 
 
I (A) 
I (B) 
I (B) 
I (B) 
I (A) 
I (B) 
 
INFLUENZA 
VACCINATION 
 Patients with cardiovascular disease should have an influenza vaccination.  I (B) 
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Appendix Table 2: Discharge Destination Codes 
Home Codes Description 
01 Discharged to home/self-care. 
06 Discharged/transferred to home care of organized home health service 
organization. 
07 Left against medical advice or discontinued care. 
50 Hospice - home 
 
Appendix Table 3: Fracture Related ICD-9 Discharge Codes 
Anatomical  
Location 
Specific fracture sites Algorithm  
Hip Femoral neck: 
- Transcervical fracture, closed 
- Pertrochanteric fracture, 
closed 
- Unspecified part of neck of 
femur, closed (Hip NOS, 
Neck of femur, NOS) 
 
Pathologic fracture of neck of femur  
Inpatient primary or secondary diagnosis 
codes [substr4(8200, 8202, 8208) or 73314] 
 
OR 
 
Carrier line or outpatient claim in any 
position with HCPCS in (27230-27248) and 
diagnosis code [substr4(8200, 8202, 8208) or 
73314] 
Pelvis-closed - Acetabulum, closed 
- Pubis, closed 
- Other specified part, closed 
- Unspecified, closed 
Inpatient primary or secondary diagnosis 
code in [substr4 8080, 8082, 8084, 8088] 
 
OR 
 
Carrier line or outpatient claim in any 
position with HCPCS in (27193-27194, 
27215-27218, 27220, 27222, 27226-27228) 
and diagnosis code in [substr4 8080, 8082, 
8084, 8088] 
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Anatomical  
Location 
Specific fracture sites Algorithm  
Leg-closed 
other than hip, 
not including 
knee or ankle 
Fracture of other and unspecified parts 
of femur 
- Shaft or unspecified part, 
closed 
- Lower end, closed (distal 
end) 
 
Fracture of patella 
 
Fracture of tibia and fibula 
- Upper end, closed 
- Shaft, closed 
- Unspecified part, closed 
(Lower leg NOS) 
 
Pathologic fracture of other specified 
part of femur (i.e. other than femoral 
neck) 
 
Pathologic fracture of tibia and fibula 
(excluding ankle NOS) 
Inpatient primary or secondary diagnosis 
code in [substr4(8210, 8212, 8220, 8230, 
8232, 8238), 73315, 73316] 
 
OR 
 
Carrier line or outpatient claim in any 
position with HCPCS in (27500-27514, 
27530-27536, 27750-27759, 27780-27784, 
27824-27828) and diagnosis code in 
[substr4(8210, 8212, 8220, 8230, 8232, 8238), 
73315, 73316] 
Ankle  
 
 
Fracture of ankle 
- Medial malleolus, closed 
(Tibia involving ankle, 
malleolus) 
- Lateral malleolus, closed 
(Fibular involving ankle, 
malleolus) 
- Bimalleolar, closed 
(Dupuytren’s fracture, fibula 
Pott’s fracture) 
- Trimalleolar, closed (Lateral 
and medial malleolus with 
anterior or posterior lip) 
- Unspecified, closed (Ankle 
NOS) 
 
Inpatient primary or secondary diagnosis 
code in [substr3(8240, 8242, 8244, 8246, 
8248)] 
 
OR 
 
Carrier line or outpatient claim in any 
position with HCPCS in (27760, 27762, 
27766, 27786, 27788, 27792, 27808, 27810, 
27814, 27816, 27818, 27822, 27823, 28430, 
28435, 28436, 28445 (includes talus)) and 
diagnosis code in [substr3(8240, 8242, 8244, 
8246, 8248)] 
Distal forearm 
 
 
Fracture of radius and ulna 
- Lower end, closed 
(distal end) 
 
Pathologic fracture of distal radius and 
ulna (Wrist NOS) 
Inpatient primary or secondary diagnosis 
code in [substr4(8134), 73312) ] 
 
OR 
 
Carrier line or outpatient claim in any 
position with HCPCS in (25600, 25605, 
25611, 25620, 25650, 25651, 25652 (includes 
ulnar styloid)) and diagnosis code in 
[substr4(8134), 73312)] 
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Anatomical  
Location 
Specific fracture sites Algorithm  
Radius/ulna-
other 
 
Fracture of radius and ulna 
- Upper end, closed (proximal 
end) 
- Shaft, closed 
- Unspecified part, closed 
 
Inpatient primary or secondary diagnosis 
code in [substr3(8130, 8132, 8138)] 
 
OR 
 
Carrier line or outpatient claim in any 
position with HCPCS in (24650, 24655, 
24665, 24666, 24670, 24675, 24685, 25500, 
25505, 25515, 25520, 25525, 25526, 25530, 
25535, 25545, 25560, 25565, 25574, 25575) 
and diagnosis code in [substr3(8130, 8132, 
8138)] 
Humerus-
closed 
 
 
Fracture of humerus 
- Upper end, closed 
- Shaft or unspecified part, 
closed 
- Lower end, closed (distal end 
of humerus, elbow) 
 
 
Pathologic fracture of humerus 
Inpatient primary or secondary diagnosis 
code in [substr4(8120, 8122, 8124), 73311] 
 
OR  
 
Carrier line or outpatient claim in any 
position with HCPCS in (23600, 23605, 
23615, 23616, 23520, 23625, 23630, 23665, 
24500, 24505, 24515, 24516, 24530, 24535, 
24538, 24545, 24546, 24560, 24565, 24566, 
24575, 24576, 24577, 24579, 24582) and 
diagnosis code in [substr4(8120, 8122, 8124), 
73311] 
Clavicle-closed  Fracture of clavicle 
- Closed 
Inpatient primary or secondary diagnosis 
code in [substr4(8100)] 
 
OR 
 
Carrier line or outpatient claim in any 
position with HCPCS in (23500, 23505, 
23515) and diagnosis code in [substr4(8100)] 
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Anatomical  
Location 
Specific fracture sites Algorithm  
Vertebral  
 
Fracture of vertebral column without 
mention of spinal cord injury 
- Cervical, closed 
- Dorsal, thoracic (closed) 
- Lumbar, closed 
- Sacrum and Coccyx, closed 
- Unspecified, closed 
 
Fracture of vertebral column with 
spinal cord injury 
- Cervical, closed 
- Dorsal, thoracic (closed) 
- Lumbar, closed 
- Sacrum and Coccyx, closed 
- Unspecified, closed 
 
 
Inpatient primary or secondary diagnosis 
code in [substr3(8050, 8052, 8054, 8056, 
8058, 8060, 8062, 8064, 8066, 8068), 73313] 
 
OR  
 
Carrier line or outpatient claim in any 
position with HCPCS in (22520, 22521, 
22522, 76012, 76013, 22305, 22310, 22315, 
22318, 22319, 22325, 22326, 22327, 22328, 
22523, 22524, 22525, S2360, S2361, S2362, 
S2363) and diagnosis code in [substr3(8050, 
8052, 8054, 8056, 8058, 8060, 8062, 8064, 
8066, 8068), 73313] 
 
 
 
  
 74 
 
Appendix Table 4: Revascularization Codes 
Revascularization  
[89, 90]  
CABG: ICD-9-CM procedure codes 36.1-36.19;  
 CPT codes 33510-33523, 33530-33536; 
Stent:  ICD-9-CM procedure codes 36.06-36.07,36.09; 
 HCPCS codes 92980, 92981, G0290, G0291; 
Angioplasty: 
 ICD-9-CM procedure codes 00.66, 36.01-36.03, 
36.05;  
 CPT codes 92982, 92984,92995, 92996; 
Thrombolytic Agents:  
 ICD-9-CM procedure codes 36.04, 99.10 
 HCPCS 36593;  
 
Appendix Table 5: Additional Baseline Comorbid Conditions 
Description ICD-9 
Code 
Cardiogenic Shock (index hospitalizations only) 785.51 
Hyperlipidemia 272.* 
Hypotension 458.* 
Gastrointestinal Bleed 578.* 
Osteoporosis 733.0* 
Osteoarthritis 715.* 
[23, 91] 
 
Appendix Table 6: Potential Confounders 
Measured: Unmeasured: 
Age, Gender, Race Marital Status 
SES (Income) Educational Attainment 
Revascularization Rehab proximity 
Functional Status Referring Physician 
Mental Status  
Medication Use  
Comorbid conditions  
Insurance Coverage  
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